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ABSTRACT 
 
DMP1, dentin matrix protein 1, was cloned from a rat dentin cDNA library 20 
years ago. Initially, this non-collagenous matrix protein was thought to be dentin specific 
and gained little interest in other scientific communities except the dental research area. 
Research that identified DMP1 mutations in humans and deletion in mice lead to the 
discovery of a novel disease: autosomal recessive hypophosphatemic rickets 
(ARHR). Functional studies reveal that DMP1 is essential for the maturation and 
functions of osteoblast and osteocyte via two possible mechanisms: 1) as a transcriptional 
factor that directly regulates osteo-/odonto-specific genes; and 2) as an extracellular 
matrix (ECM) protein, which controls bone and dentin mineralization. However, both 
theories appear controversy. Besides, the mechanism by which ARHR patients or Dmp1-
null mice develop osteomalacia is largely unknown.   
In this study, we initially targeted DMP1 either in the nucleus only by replacing 
the endogenous signal peptide with the NLS signal peptide (named NLSDMP1), or 
targeted it in the ECM by using its own signal secretive peptide with the same 
recombinant DMP1 protein (named SPDMP1). The NLSDMP1 transgene, when expressed 
in the Dmp1-null osteoblast and osteocyte in vivo, failed to rescue the Dmp1-null 
phenotype, whereas the SPDMP1 transgene fully rescued the skeletal abnormalities of 
Dmp1-null mice, indicating that DMP1 functions as an ECM protein in vivo.  
In a separate research, we revealed an elevated β-catenin expression level in 
Dmp1-KO osteocytes, besides, the targeted expression of β-catenin in the osteocyte 
recaptured the osteomalacia phenotype, similar to that in Dmp1-KO mice. Furthermore, 
the targeted expression of DKK1 (a potent inhibitor of Wnt/β-catenin) in Dmp1-KO 
osteoblasts by crossing Dmp1-KO and 2.3 Col 1-Dkk1 mice, resulting in consequent 
blockade of Wnt/β-catenin signaling, significantly improved the rachitic/osteomalacic 
phenotype. The results of this study will expand our understanding of how the osteocytes 
regulate bone development and mineralization during the early postnatal period. In 
addition, this study has clinical relevance, as a high Pi diet alone fails to fully restore the 
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osteomalacic status in patients, and normalizing the Wnt/β-catenin signaling may benefit 
these patients. 
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NOMENCLATURE 
 
ADHR Autosomal dominant hypophosphatemic rickets 
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APC Adenomatous polyposis coli  
BSP Bone sialoprotein 
BSEM Backscattered scanning electron microscopy 
BrdU 5-Bromo-2’-deoxyuridine 
µCT Microcomputed tomography 
Cont Control group 
CA-β Constitutive activated β-catenin 
Ca Calcium  
CKO Conditional knockout 
Ck1 Casein kinase 1 
DMP1 Dentin matrix protein 1 
nuDMP1 Nuclear isoform of DMP1 
Dn Dentin  
pDn Predentin 
DSPP Dentin sialophosphoprotein 
DKK1 Dickkopf-related protein 1 
Dvl Disheveled 
ECM Extracellular matrix 
ERK Extracellular signal-regulated kinase  
ER Endoplasmic reticulum  
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Gsk3β Glycogen synthase kinase 3β  
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HE Hematoxylin & Eosin  
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IWR Compound inhibitors of Wnt response  
KO Conventional knockout 
LacZ β-Galactosidase 
LEF Lymphoid enhancing factor  
LRP5/6 Low-density lipoprotein receptor-related protein 5/6 
MEPE Matrix extracellular phosphoglycoprotein 
MAPK Mitogen-activated protein kinase 
MEK Mmitogen-activated protein kinase kinas 
M1V Mut Met1Val  mutation 
NCPs Non-collagenous  proteins 
NLS Nuclear localization signal peptide 
OSX Osterix 
OPN Osteopontin 
OCN Osteocalcin 
Ocy Osteocyte 
Ob Osteoblast 
PHEX Phosphate-regulating neutral endopeptidase, X-linked  
PTHR Parathyroid receptor  
PL Periodontal ligament 
P Pulp  
Pi Phosphorus  
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RGD Arginine-glycine-aspartic acid 
Runx2 Runt-related transcription factor 2 
RBC Red blood cell 
SIBLINGs Small integrin-binding ligand, N-linked Glycoprotein 
SEM Scanning electron microscopic 
SOST Sclerostin 
SP Secretory signal peptide 
SF Significant difference  
SR Sirius red staining 
SHH Sonic hedgehog  
SAPK Stress-activated protein kinase 
TCF T cell factor  
WT Wild type 
XLH X-linked dominant hypophosphatemic rickets  
 
 ix 
 
TABLE OF CONTENTS 
                                                                                                                                        Page 
ABSTRACT ...................................................................................................................... ii 
DEDICATION ................................................................................................................. iv 
ACKNOWLEDGEMENTS .............................................................................................. v 
NOMENCLATURE ......................................................................................................... vi 
TABLE OF CONTENTS ................................................................................................. ix 
LIST OF FIGURES .......................................................................................................... xi 
LIST OF TABLES ......................................................................................................... xiv 
CHAPTER I  INTRODUCTION AND LITERATURE REVIEW .................................. 1 
     Specific Aims ................................................................................................................1 
     Review of the Literature ............................................................................................... 3 
CHAPTER II  CONSTITUTIVE NUCLEAR EXPRESSION OF DMP1 FAILS
TO RESCUE THE DMP1-NULL SKELETAL PHENOTYPE ......................................13 
     Overview .....................................................................................................................13 
     Synopsis ......................................................................................................................13 
     Introduction .................................................................................................................14 
     Experimental Procedure ..............................................................................................16 
     Results .........................................................................................................................22 
     Discussion ...................................................................................................................26 
CHAPTER III  NUCLEUS-TARGETED DMP1 FAILS TO RESCUE 
DENTAL DEFECTS IN DMP1 NULL MICE ................................................................30 
     Synopsis ..................................................................................................................... 30 
     Introduction .................................................................................................................30 
     Materials and Methods ................................................................................................32 
     Results .........................................................................................................................34 
     Discussion .................................................................................................................. 37 
 x 
 
     Discussion ...................................................................................................................52 
CHAPTER V  CONCLUSION ........................................................................................ 56 
     Important Roles of Osteocytes .....................................................................................56 
     Signaling Involved in the Biological Regulation of DMP1 .........................................57 
     Pathogenesis of the Inherited Hypophosphatemic Rickets/Osteomalacia ...................59 
REFERENCES ................................................................................................................. 60 
APPENDIX A FIGURES ................................................................................................. 80 
APPENDIX B TABLES ................................................................................................ 128 
 
 
 
CHAPTER IV  A KEY PATHOLOGICAL ROLE OF WNT/Β-CATENIN 
IN HYPOPHOSPHATEMIC RICKETS .......................................................................... 39 
     Synopsis .......................................................................................................................39 
     Introduction .................................................................................................................40 
     Subjects and Methods ...................................................................................................42 
     Results ..........................................................................................................................47 
 xi 
 
LIST OF FIGURES 
                                                                                                                                       Page 
Figure 1-1  Photographs and radiographs of patients with hypophosphatemic rickets 
                   osteomalacia .................................................................................................. 80 
Figure 1-2  Schematic structure of the human DMP1 gene and ARHR mutations. ......... 81 
Figure 1-3  Defective osteocytes are responsible for abnormal bone formation in the  
                   Dmp1 knockout mice ..................................................................................... 82 
Figure 1-4  SEM images of the acid-etched, resin-casted osteocyte-canalicular system. 84 
Figure 1-5  Roles of DMP1 in control of osteocyte maturation ....................................... 85 
Figure 1-6  Proposed models for DMP1 control genes critical for osteogenesis ............. 86 
Figure 1-7  Schematic representation of ostoecytes and their connections ...................... 87 
Figure 2-1  Dmp1 is expressed in postnatal osteoblasts and responsible for regulating  
                   osteoblast proliferation and differentiation ................................................... 88 
Figure 2-2  Transfection of Ad-CMV-NLSDMP1 or Ad-CMV-SPDMP1 greatly  
                   changed expressions of bone markers in MC3T3 cells ................................. 90 
Figure 2-3  NLSDMP1 expressed in the nuclei and SPDMP1 mainly secreted in the  
                   matrix ............................................................................................................ 91 
Figure 2-4  NLSDMP1 revealed no cure of rachitic phenotypes in Dmp1-null mice,  
                   however SPDMP1 fully rescued the defects ................................................... 92 
Figure 2-5  Targeting DMP1 in the Dmp1-KO nuclei did not rescue deficiencies of  
                   mineralization in Dmp1-null mice, however re-expressing DMP1 in the  
                   matrix greatly recovered these defects. ......................................................... 94 
Figure 2-6  IHC analysis shown the targeted expression of NLSDMP1 transgene  
                   revealed no rescue of the maturational defects in ostecytes .......................... 95 
Figure 2-7  The targeted expression of NLSDMP1 transgene (line #97) in either the  
                   Dmp1 HET or the KO background had no effect ......................................... 96 
Figure 2-8  The in vivo working model ............................................................................ 98 
Figure 3-1  Tooth phenotypes in an M1V Mut ARHR patient ........................................ 99 
 xii 
 
Figure 3-2  Nucleus-targeted Dmp1 expressed in the pre-odontoblasts and  
                   odontoblassts, showing no morphological improvement of Dmp1-null  
                   tooth. ............................................................................................................ 100 
Figure 3-3  Nucleus-targeted Dmp1 had no rescue of the dental abnormalities of  
                   Dmp1-null mice ........................................................................................... 101 
Figure 3-4  Dmp1-null mice developed typical periodontitis ......................................... 103 
Figure 3-5  Nucleus-targeted Dmp1 had no improvement of periodontal structures ..... 104 
Figure 3-6  Nucleus-targeted Dmp1 showed no effect on tooth eruptional delay ........ 106 
Figure 3-7  Statistic analysis of root morphology and osteoclast numbers, radiographs 
                   of Line #97 .................................................................................................. 107 
Figure 4-1  A sharp reduction of SOST expression in the 3-wk-old cortical bone of  
                   Dmp1-null mice ........................................................................................... 108 
Figure 4-2  Wnt/β-catenin signaling is up regulated in the osteocyte of Dmp1-null  
                   mice. ............................................................................................................ 109 
Figure 4-3  Constitutive stabilization of β-catenin in osteocyte lead to abnormal bone  
                   structures at age of 3-week-old ................................................................... 110 
Figure 4-4  Constitutive stabilization of β-catenin in osteocyte recaptured  
                   osteomalacia phenotype and displayed deformed osteocytes ..................... 112 
Figure 4-5  Immunohistochemistry staining of DMP1, DKK1, and β-catenin .............. 114 
Figure 4-6  Normalizing the Wnt/β-catenin activity greatly improves the bone  
                   morphology ................................................................................................. 114 
Figure 4-7  The abnormal bone homestasis in Dmp1-null metaphysis is improved by  
                   Dkk1-Tg ....................................................................................................... 116 
Figure 4-8  Osteomalacia phenotype in Dmp1-null mice is greatly restored by  
                   Dkk1-Tg ....................................................................................................... 118 
Figure 4-9  Osteocyte maturation defect in Dmp1-null mice is greatly improved by  
                   Dkk1-Tg ....................................................................................................... 120 
Figure 4-10  Hyp-mice displayed increased β-catenin level and Dkk1-transgene  
                     shown a morphological rescue in Hyp-mice ............................................. 122 
 xiii 
 
                     rickets/osteomalacia deficience in Dmp1-null mice .................................. 124 
Figure 4-12  The pathogenesis of the inherited hypophosphatemic ricket/osteomalacia  
                     in Dmp1-null or Hyp-mice ........................................................................ 126 
Figure 5-1  Signaling pathways underlying the osteocyte maturation and function  
                   process that regulated by DMP1 ................................................................. 127 
 
Figure 4-11  Injection of anti-β-catenin compound drug improves the  
 xiv 
 
LIST OF TABLES 
                                                                                                                                       Page 
Table 1-1  Characteristics of ARHR patients and mice models ..................................... 128 
Table 2-1  Three independent lines and their DMP1 expressions .................................. 129 
Table 2-2  RNA expression levels after transfection ..................................................... 130 
Table 2-3  Bone histomorphometry findings in the femurs of 3-week-old mouse ........ 131 
Table 4-1  Hypophosphatemia phenotype in Dmp1-null mice is partially rescued by  
                  Dkk1-Tg ........................................................................................................ 132 
 
 
 
 1 
 
CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Specific Aims 
Rickets is a softening of bones in children due to deficiency or impaired 
metabolism of vitamin D, phosphorus or calcium, potentially leading to fractures and 
disturbance of normal ossification, marked by bending and distortion of the bones, 
nodular enlargements on the ends and sides of the bones, delayed closure of the 
fontanelles, and muscle pain. Rickets is among the most frequent childhood diseases in 
many developing countries. The adult equivalent of rickets is named as osteomalacia, 
which contains inadequate or delayed mineralization of osteoid in mature cortical and 
spongy bone. Hypophosphatemic rickets/osteomalacia is a group of disorders 
characterized by rickets associated with hypophosphatemia, resulting from dietary 
phosphorus deficiency, defects in renal tubular function, or, most frequently, inherited 
gene mutations. Studies demonstrated several gene mutations will result in 
hypophosphatemic rickets, such as, mutations in Phex gene lead to x-linked dominant 
hypophosphatemic rickets (XLH) (1), Fgf23 mutant results in autosomal dominant 
hypophosphatemic rickets (ADHR) (2), and homozygous mutation in Dmp1 that cause 
autosomal recessive hypophosphatemic reickts (ARHR) (3). This study works on the 
ARHR that is attributed to Dmp1 mutations in humans or Dmp1 deletion in mice. We 
propose to investigate the underlying mechanism, especially the signaling pathway, 
which plays a key pathological role during the development of hypophosphatemice 
rickets/osteomalacia. Furthermore, for the consideration of translational medicine of this 
study, we will try to rescue the rickets/osteomalacia in Dmp1-null mouse model using 
drugs, which target the identified signaling pathway. Our focus is on how DMP1 
regulates osteocyte maturation and function that respond to bone morphology and 
mineralization defects in the hypophosphatemice rickets/osteomalacia mice. The results 
of this study will also cast light on the understanding of how the osteocytes regulate 
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bone development and mineralization during the early postnatal period. The specific 
aims are listed as the following: 
Specific Aim 1: To investigate whether DMP1 works as a co-transcription factor 
that will be transported into the nucleus to regulate related gene expression. We will first 
test DMP1 function in vitro by generating two different constructs that lead to different 
subcellular location of DMP1. The SPDMP1 construct contained a signal peptide that 
directed the extracellular transport of DMP1. We then generated transgenic mice that 
express DMP1 in the nucleus (NLSDMP1) for an in vivo study. We hypothesize that 
NLSDMP1 neither regulates osteocytes maturation nor rescues rickets/osteomalacia 
phenotype. 
Specific Aim 2: To investigate whether the expression of canonical Wnt/β-
catenin signaling is changed in Dmp1 deletion induced ARHR mouse models, and to 
further understand which kind of bone cells are responsible for canonical Wnt/β-catenin 
signaling. We will examine the expression pattern of Wnt/β-catenin signaling in Dmp1-
null mice. We hypothesize that in ARHR mice the deletion of Dmp1 leads to an up-
regulation of canonical Wnt/β-catenin signaling mainly in osteocytes. 
Specific Aim 3: To rescue the rickets/osteomalacia phenotype in Dmp1-null mice 
by down-regulating the β-catenin expression. We will cross our Dmp1-KO mice with 
Dkk1-Tg mice. Their offspring will be evaluated for the morphology and mineralization 
of bone, cartilaginous development, serum biochemistry, maturation and function of 
bone cells. We hypothesize that re-regulating β-catenin in Dmp1 knockout mice using 
the Dkk1 transgene may rescue the rickets/osteomalacia phenotype via reinvigorating 
osteocyte maturation. 
Specific Aim 4: To further confirm that increased function of Wnt/β-catenin 
signaling in the osteocytes that may cause its maturational and functional defects, 
leading to osteomalacia. We have specifically induced β-catenin expression in the 
osteocyte both in vitro and in vivo. Gene expression and mineral formation, morphology 
and mineralization of bone, serum biochemistry, maturation and function of osteocytes 
were evaluated. We hypothesize that it is the evaluated expression of Wnt/β-catenin 
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signaling in osteocytes that will cause their maturational and functional defects, leading 
to rachitic phenotype. 
 Specific Aim 5: To address the clinical translation of our studies. A compound-
drug that inhibits Wnt/β-catenin signaling will be used to treat Dmp1-null rickets mice. 
Mice will be collected and evaluated after treatment. We hypothesize this compound, 
named as “IWR”, can greatly improve the rickets/osteomalacia phenotypes of Dmp1-null 
mice.   
Together these aims will further our understanding of how DMP1 regulates 
osteocyte maturation, and the pathological role of canonical Wnt/β-catenin signaling 
during the development of rickets/osteomalacia phenotype. These results will help 
explain why a high Pi diet alone fails to fully restore the osteomalacic status in patients 
and the restoration of phosphate homeostasis by FGF-23 antibodies only partially 
rescued the bone formation rate and osteomalacia. Moreover, they also provide a new 
comprehensive and a possible clinic therapy for patients with hypophosphatemic 
reickts/osteomalacia. 
 
Review of the Literature 
The extracellular matrix (ECM) of bone and dentin contains numerous non-
collagenous proteins (NCPs). One of the categories of NCPs is termed the “Small 
Integrin-Binding Ligand, N-linked Glycoprotein (SIBLINGs) family” based on the 
similarities of the intron/exon properties, conserved protein biochemical properties (such 
as unstructured and acidic), and specific peptide motifs (e.g., phosphorylation and 
integrin-binding RGD). There are five members in this SIBLINGs family: Dentin matrix 
protein 1 (DMP1), bone sialoprotein (BSP), osteopontin (OPN), enamelin, matrix 
extracellular phosphoglycoprotein (MEPE), and dentin sialophosphoprotein (DSPP) (4). 
DMP1 was originally identified by cDNA cloning from the rat dentin matrix (5) and was 
initially believed to be dentin specific but was later observed in bone matrices at a much 
higher level (6,7). Studies suggested that DMP1 initiates its expression at E15.5 and 
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resides mainly in osteoblasts during embryonic development. However, DMP1 is 
predominantly expressed in the osteocytes during postnatal development (8,9).  
The Dmp1 gene was mapped to the long (q) arm of chromosome 4 at position 21 
(4q21) in humans and to 5q21 in mice. Dmp1 is encoded by 6 exons with 80% of its 
coding information in exon 6. There are two promoter control domains: a proximal one 
located between the -2.4 kb and the +4 kb region, and a distal one between the -2.4 kb 
and -9.6 kb region. The proximal domain controls the early stages of DMP1 expression, 
and the distal domain controls the later stages (10). AP-1, JunB, Runx2, Msx1/2, 
Tcf/Lef, C/EBP, and YY-1 are essential transcription factors for bone and tooth tissue-
specific regulation. The potential response elements for these transcription factors have 
been identified in the mouse Dmp1 promoter (11).  
 
DMP1 mutation/deletion leads to autosomal recessive hypophosphatemia  
In vivo animal studies showed that DMP1 has potential functions in non-
mineralized tissues such as in brain (12), kidney (13) and salivary tissues (14), although 
this matrix protein is mainly expressed in mineralized tissues and plays an important role 
during osteogenesis (15). For example, DMP1 is thought to actively promote and control 
the mineralization of collagen fibers and crystal growth within osteoids and predentin 
when these tissues are converted to mature bone and dentin (15). In addition, DMP1 is 
considered to regulate and support the maturational process converting osteoblasts to 
osteocytes and preodontoblasts to odontoblasts (16). Importantly, DMP1 mutations in 
humans or the deletion of Dmp1 in mice lead to autosomal recessive hypophosphatemic 
rickets (ARHR)/osteomalacia (3). It is noteworthy that, unlike other genetic disease 
cases in which human mutations are identified first and then animal studies such as gene 
knockouts are performed, it is the Dmp1-null mouse research results (17,18) that have 
triggered searches for DMP1 mutations in humans.  
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Autosomal recessive hypophosphatemia 
Rickets is the softening of bones in children because of a deficiency or impaired 
metabolism of vitamin D, phosphorus or calcium. This disease not only interrupts child 
development but also can potentially lead to fractures and disturbance of normal 
ossification. Rickets due to nutrition deficiency is more common in children in 
developing countries. The adult equivalent of rickets is known as “osteomalacia”, a 
disease characterized by inadequate or delayed mineralization of osteoids in mature 
cortical and spongy bones. Hypophosphatemic rickets/osteomalacia is a group of 
disorders characterized by hypophosphatemia, which mainly results from disorders of 
renal phosphate wasting (Unlike the situation with calcium, there is no rickets due to 
phosphorus deficiency, since one’s daily diet is rich in this element). There are several 
inherited gene mutations responsible for deficiencies in reabsorption of the renal tubule 
that result in hypophosphatemia. For example, mutations in the PHEX gene lead to x-
linked dominant hypophosphatemic (XLH) rickets (1), FGF23 mutations result in 
autosomal dominant hypophosphatemic rickets (ADHR) (19), and homozygous 
inactivating mutations in DMP1 cause autosomal recessive hypophosphatemic rickets 
(ARHR)/osteomalacia (3,20,21).  Comparisons of patients having XLH, the most 
common hypophosphatemic rickets, it has shown that fewer than 10 cases of kindred 
ARHR have been identified worldwide due to the autosomal recessive nature of the 
DMP1 mutations (3,20-23) (Fig. 1-1). Molecular genetic analysis of these cases revealed 
the following changes: 1) the deletion of nucleotides 1484-1490 in exon 6 (1484-
1490del) resulting in a frameshift that replaced the 18 conserved C-terminal residues 
with 33 unrelated residues, or another deletion in the same exon leading to a frameshift 
replacing 335 conserved amino acids with 53 unrelated ones; 2) a mutation in the start 
codon (1A→G) causing a methionine to valine change (M1V); 3) a homozygous 1-bp 
deletion in exon 6 (362delC) led to the placement of a premature stop codon after 120 
unrelated amino acids; 4) a biallelic nucleotide substitution at nucleotide 98 in exon 3 
(98G→A) introduced a premature termination codon (PTC) at codon 33, which replaced  
the wild type tryptophan residue (W33X); and 5) a mutation at the splice acceptor 
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junction of exon 6 (IVS5-1G→A) and intron 2 (55-1G→G) is predicted to alter pre-
mRNA splicing, which results in a shift in the open-reading frame if the final message is 
stable (Fig. 1-2). 
Based on the reported cases, the primary clinical symptoms of ARHR include: 
lower limb deformities (bowed legs or knock-knees), waddling gait, short stature or 
stunted growth, tooth abscesses or early loss of teeth, bone and muscle pain, biochemical 
abnormalities (hypophosphatemia with normal levels of serum calcium and parathyroid 
hormone).  More severely afflicted patients may also suffer from nerve deafness, facial 
and dental abnormalities, learning disabilities, joint pain, and contracture and 
immobilization of the spine. Patients diagnosed with ARHR display symptoms in their 
early childhood that are likely to have a wide spectrum of severity, depending on the site 
and size of the mutations and the severity and chronicity of the associated phosphate 
depletion (24) (Table 1-1).  
Dmp1-null mice do not have apparent abnormalities during prenatal bone 
development.  However, they are severely impaired after birth with a chondrodysplasia-
like phenotype characterized by short and widened long bones having flared and 
irregular metaphyses and delayed malformed ossification centers in postnatal 
development (18). Compared with human patients, Dmp1-null animals displayed 
significantly lower serum phosphorus levels than the wild type controls. This difference 
is due to the increased urinary phosphate excretion associated with increased FGF23 
levels. Furthermore, the levels of 1,25-dihydroxyvitamin D [1,25(OH)2D3] were 
inappropriately normal, whereas the serum PTH level significantly increased in the 
Dmp1-null mice (3,16,25). Bone histological studies demonstrated that the Dmp1-null 
mice displayed severe osteomalacia bone changes with significant reduction in bone 
mineralization. Furthermore, the Dmp1-null mice had increased osteoid and more porous 
cortical bone. Under higher-magnification back-scattered scanning electron microscopic 
(SEM) images, the minerals, which are evenly distributed around the osteocyte lacunae 
in normal condition, were either absent or sparsely located in regions surrounding the 
Dmp1-null osteocytes. The scanning transmission electron microscopic images indicated 
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a much lower content of mineral, calcium, and phosphorus in the Dmp1-null mineralized 
matrix (3,16,25) (Fig. 1-3, a-b). 
 
Osteocyte maturational defects in Dmp1-null mice  
Numerous studies have consistently suggested the key pathological cause 
responsible for the ARHP phenotype in Dmp1-null mice is the maturational and 
functional defects of the osteocytes (3,16,25) (Fig. 1-3, c). 
The osteocytes reside in lacunae within the mineralized bone matrix and send 
their dendritic processes (ranging from 40–100 per cell) through tiny tunnels called 
“canaliculi” to form the osteocyte lacunocanalicular network (26). As the osteocytes 
mature, numerous cellular projections form and elongate. Next, their cell volume and 
ultrastructure, such as the endoplasmic reticulum and the Golgi apparatus, are reduced, 
and a well-organized lacunocanalicular system is built up (26).  Compared to the well-
established smooth inner wall of the lacunae and canaliculi, Dmp1-null osteocytes 
display bulky and coarse microstructural features, as well as abnormally enlarged and 
round-shaped osteocytes accompanied by a reduction in dendrite numbers (3,16,25).  
An early transfection study of MC3T3-E1 cells that expressed excessive DMP1, 
displayed accelerated differentiation of osteoblasts and an earlier onset of mineralization, 
suggesting that DMP1 plays an important role during the osteoblast differentiation, as 
well as osteocyte maturation and function (27).  It was later reported that patients with 
DMP1 mutations or mice with Dmp1 deletion did not display any gross abnormalities 
during the embryonic period or at birth (28). However, they generally appeared to have 
the ARHP phenotype during their early postnatal development, when DMP1 is highly 
produced by osteocytes and secreted into the mineralized matrix. Further analysis 
indicated that Dmp1 deletion leads to defects primarily in the osteocytes (3,16,25), cells 
that account for more than 95% of bone cells (Fig. 1-4).  
There is general agreement that dramatic decreases in protein expression and 
metabolic activity occur during the maturation of osteoblasts into osteocytes (29). 
However, the analysis of Dmp1-null mice showed sharp increases of osteoblastic marker 
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expression levels, such as runt-related transcription factor 2 (RunX2), osterix (OSX), 
Collagen I (Col I), alkaline phosphatase (ALP), bone sialoprotein (BSP), and osteocalcin 
(OCN). In addition, the early osteocyte marker E11/gp38 is widely and increasingly 
expressed throughout the whole cortical bone layer in the Dmp1-null mice. In contrast, 
sclerostin (SOST), mainly expressed in mature osteocytes, is greatly reduced. These 
studies indicated that osteocyte differentiation is likely regulated by DMP1 (3,16,25). 
There is strong evidence showing that the osteocytes, the terminally differentiated cells, 
regain the ability to divide and proliferate in Dmp1-null mice (3,16,18,25,30) (Fig. 1-5).   
 
DMP1 regulates osteocyte biology and bone development 
As previously mentioned, DMP1 is essential for osteogenesis by regulating the 
maturational process of osteoblasts to osteocytes and bone mineralization during 
postnatal development. As a key regulator, DMP1 performs several functions in 
osteocyte biology and bone development as described below. 
 
DMP1 directly promotes hydroxyapatite formation in vitro 
The initial finding linking DMP1 with mineralization was based on the close 
association of the DMP1 expression and the in vitro "bone nodule" formation in primary 
rat calvarial cell cultures (8). Soon after, He and colleagues (31) reported that the 
specific acidic clusters in DMP1 molecules can provide the molecular design necessary 
for controlling the formation of oriented calcium phosphate crystals and that the self-
assembly of acidic clusters into a beta-sheet template of DMP1 is likely required for the 
role of DMP1 in biomineral induction. Gajjeraman et al. also showed that both full-
length recombinant DMP1 and native DMP1 C-terminal fragments isolated from rat 
bone accelerated the nucleation of hydroxyapatite in the presence of type I collagen, 
whereas the N-terminal domain of DMP1 (amino acid residues 1-334) inhibited 
hydroxyapatite nucleation (32). Further analysis of the three DMP1 fragments within the 
mineralized tissues [N-terminal, C-terminal, and a chondroitin-sulfate-linked N-terminal 
fragment (DMP1-PG)] implies that both the C-terminal and N-terminal fragments are 
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promoters of hydroxyapatite formation and growth, while DMP1-PG is an inhibitor (33). 
These findings appear controversial although they indicate that distinct forms of DMP1 
may work collectively to control the mineralization process in different ways. However, 
the direct role of DMP1 in mineralization described above is mainly based on in vitro 
culture studies with little in vivo evidence. 
 
DMP1 signaling  
DMP1 signals via cell surface integrin  
In vitro studies have shown that DMP1 promotes cell attachment through the 
RGD motif in a cell- and tissue-specific manner, suggesting a possible interaction of this 
protein with specific cells and activating signaling pathways. This speculation is 
strengthened by the observation that exogenous DMP1 added to the exposed dental pulp 
may act as a morphogen trigger and/or promoter of the differentiation of undifferentiated 
ectomesenchymal cells in the pulp toward the odontoblast lineage. A further in vitro 
analysis demonstrated that either the full-length DMP1 or the 57-kDa fragment can 
activate phosphorylated extracellular signal-regulated kinase (p-ERK). The difference 
between them is that the effect of the 57-kDa fragment lasted longer than that of the full-
length protein (34). More recently, two separate studies confirmed that the matrix DMP1 
has the ability to activate the ERK-MAPK (extracellular signal-regulated kinase-
mitogen-activated protein kinase) pathways via interaction with cell surface αvβ3 
integrin. It also further stimulates the translocation of phosphorylated JNK to the 
nucleus, as well as a concomitant up-regulation of transcriptional activation by 
phosphorylated c-Jun, such as Runx2 activation (35,36) (Fig. 1-6, a). 
 
DMP1 works as a transcriptional factor  
As mentioned above, DMP1 is generally considered to be an extracellular matrix 
protein. However, some in vitro studies showed the expression of DMP1 in the nuclei of 
several cell lines: MC3T3-E1, C3H10T1/2, and 17IIA11 (37,38). These studies suggest 
that DMP1 could function as a transcriptional factor. Moreover, Narayanan et al. 
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reported a functional nuclear localization signal (NLS) peptide at the carboxyl terminal 
of DMP1 and thought that this signal peptide could bring DMP1 into the nucleus (37). 
They then found a specific domain in the N-terminal of DMP1 that interacted with the 
glucose-regulated protein-78 (GRP-78) receptor leading to the internalization and 
nuclear localization of full-length DMP1 (39). Recently, Siyam et al. reported finding 
two DMP1 subpopulations in non-synchronized cells: one in the nucleus and one in the 
cytoplasm (38). Nevertheless, this transcriptional factor theory is mainly supported by 
the in vitro cell line studies with little in vivo evidence. Importantly, Lu and colleagues 
reported that the 57 kDa C-terminal fragment of DMP1 is sufficient to fully rescue the 
rachitic abnormalities found in the Dmp1-null mice (25). However, more in vivo studies 
are required to support this transcriptional factor theory (Fig. 1-6, b).  
 
Pathophysiologic regulation  
Recent findings showed that osteocytes embedded in the mineralized bone matrix 
are far more important than previously described in the literature (Fig. 1-7). These 
studies imply that osteocytes are multifunctional cells that connect to themselves, to cells 
on the bone surface and to the vasculature, and they play a key regulatory role in bone 
and mineral homeostasis under normal and pathological conditions during postnatal 
development (29). As a crucial protein mainly produced by osteocytes, DMP1 is 
responsible for the pathophysiologic development of the heritable disorders of rickets 
and osteomalacia by impacting the regulatory effect of osteocytes (24). 
 
Regulating the axis of FGF23-renal phosphorus reabsorption-serum phosphorus level 
Prior studies demonstrated that serum FGF23, which is released from bone, 
targets the kidneys and decreases the expression of the sodium/phosphate cotransporters: 
NaPi-IIa and NaPi-IIc. These co-transporters are required for renal phosphate 
reabsorption, and a decrease in co-transporter expression will lead to an increase of the 
urinary excretion of phosphate and a decrease of serum phosphate levels (40). 
Additionally, FGF23 also down-regulates the production of 1-α hydroxylase, resulting in 
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a decreased conversion of 1,25(OH)2D3 to the active vitamin D metabolite, 
1,25(OH)2D3.  This reduced production leads to a decreased expression of NaPi-IIb, a 
third sodium/phosphate co-transporter, and therefore affects phosphate absorption in the 
intestine (41). It is generally agreed that the functional axis of the FGF23 renal and 
intestinal phosphorus reabsorption serum phosphorus level is the key systematic 
pathological mechanism responsible for the development of inherited hypophosphatemic 
rickets/osteomalacia. Studies of Dmp1-null mice and DMP1 mutations in patients 
showed that FGF23 is significantly up-regulated in osteocytes, which is released into 
circulation through the connection between osteocytes and vessels, leading to an 
increase of FGF23 in serum and in subsequent hypophosphatemia (3).  Specifically, in 
situ hybridization (measuring mRNA levels) or immunohistochemistry (measuring 
protein levels), revealed that the FGF23 level in control osteocytes was much lower than 
that in osteoblasts, indicating differential regulatory mechanisms for FGF23 in bone 
cells of healthy versus disease conditions.  The discovery of elevated level of FGF23 in 
the Dmp1-null osteocytes indicates that bone is an endocrine organ regulating phosphate 
homeostasis (42) (Fig. 1-7).  
 
Canonical Wnt/β-catenin pathway  
In addition to controlling FGF23 levels, DMP1 may regulate hypophosphatemic 
rickets/osteomalacia disorder via the canonical Wnt/β-catenin signaling pathway. In 
normal bone development, the canonical Wnt/β-catenin pathway is required for 
osteogenesis and bone remodeling via regulation of early osteoblast lineage (43). 
However, recent studies have indicated that a high level of β-catenin may cause bone 
defects in rickets (44). This pathological change is likely due to a dramatic decrease in 
the expression levels of SOST (a potent inhibitor of the Wnt/β-catenin pathway(45)) in 
the Dmp1-KO osteocytes. In addition, the expression level of DKK1, another antagonist 
of the Wnt signaling pathway (46), is low in Dmp1-null mice. As a result, the canonical 
Wnt/β-catenin signaling is abnormally upregulated in Dmp1-null mice. A pilot study by 
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Lin et al. showed that normalization of the β-catenin level by overexpressing DKK1 
significantly improved the osteomalacia phenotype of Dmp1-null mice (Fig. 1-7).  
 
Summary 
DMP1 was cloned 20 years ago (5). Since then, great progress has been made, 
including gene regulation, biochemical characterization, cell/tissue localization and 
function, as well as identification of DMP1 mutations in ARHR patients. It is now clear 
that the full-length DMP1 is not biologically active and is cleaved into the 37 kDa N-
terminal and the 57 kDa C-terminal fragments. The latter is the key functional form of 
DMP1. There is strong evidence that DMP1, highly expressed in dentin and bone, is 
critical for mineralization, although the direct role of DMP1 on the formation of 
hydroxyapatite is largely based on the in vitro non-cell model with little in vivo 
evidence. The development of different forms of Dmp1 transgenic mouse models such as 
conventional and conditional null mice, the full length and the C-terminal forms of over-
expressed Dmp1 transgenic mice, and the Dmp1 point mutation models have started to 
reveal the in vivo functions of DMP1 in bones and teeth during development 
(25,28,34,47).  Because DMP1 controls the maturation of both odontoblasts and 
osteoblasts, defects in this process result in sharp changes in dentin morphologies (such 
as dentin tubules) and bone (especially the osteocyte-canalicular system). Finally, 
studies of abnormal FGF23 production in the Dmp1-null osteocytes have led to the 
discovery of DMP1 mutations in humans.  Altogether, the accumulated data from 
different laboratories strongly support the theory that DMP1 is a key player in the 
control of osteocyte and bone biology. 
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CHAPTER II 
CONSTITUTIVE NUCLEAR EXPRESSION OF DMP1 FAILS TO RESCUE THE 
DMP1-NULL SKELETAL PHENOTYPE 
 
Overview  
It is widely believed that DMP1 functions not only as a matrix protein but also as 
a transcription factor. However, this study found that nuclear activities of DMP1 didn’t 
recover the defects in Dmp1-null mice, whereas the secreted DMP1 fully rescued. We 
concluded DMP1 mainly functions as an extracellular matrix protein in vivo. This is the 
first evaluation of the biological functions of DMP1 in different subcellular locations 
(nuclear and extracellular matrix) in vivo.  
 
Synopsis 
Dentin Matrix Protein 1 (DMP1) plays multiple roles in bone, tooth, phosphate 
homeostasis, kidney, salivary gland, body balance, reproductive cycles, and the 
development of cancer. Previous in vivo studies have demonstrated its key role in 
osteocytes. However, recent in vitro studies have indicated DMP1 may also be expressed 
in the osteoblasts, and during the differentiation and maturation of 
osteoblasts/osteocytes, it has two different biological roles: 1) As a matrix protein, 
DMP1 interacts with αvβ3 integrin and activates MAP kinase signaling; and 2) DMP1 
serves as a transcription factor. This study attempted to determine whether DMP1 
expressed in the osteoblasts and works as a transcription factor that regulates osteoblast 
functions in vivo. We first identified that DMP1 continues its expression in osteoblasts 
during postnatal development and that the deletion of Dmp1 leads to an increase in 
osteoblast proliferation. Then using the adenovirus construct, we targeted the 
expressions of DMP1 either in the nucleus only by replacing the endogenous signal 
peptide with a nuclear localization signal (NLS) sequence (referred to as NLSDMP1) or as 
the WT type (referred to as SPDMP1) in the MC3T3 osteoblast for gene expression 
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comparisons. High levels of DMP1 in either form greatly increased cell differentiation in 
an identical manner. However, the targeted NLSDMP1 transgene, driven by a 3.6 kb rat 
Col 1α1 promoter in the nucleus of osteoblasts and osteocytes, failed to rescue the 
Dmp1-null mouse phenotype, whereas the SPDMP1 transgene rescued the rickets 
phenotype. These studies support the theory that DMP1 functions as an extracellular 
matrix (ECM) protein, rather than a transcription factor in vivo.  
 
Introduction  
DMP1 was originally isolated from rat dentin matrices (48) and later was found 
to have a broader expression profile in many tissues, such as bone, cartilage, salivary 
gland, kidney, pituitary gland, and blood vessels, as well as cancer tissues, such as those 
in lung and breast (6,7,12,13,49-54). This acidic phosphorylated extracellular matrix 
protein belongs to the Small Integrin-Binding Ligand, N-linked Glycoprotein 
(SIBLING) family (55,56). Like other SIBLING family members, the Dmp1 gene is 
located on chromosome 4q21 in humans and 5q21in mice (49,55). The mutation in this 
gene results in autosomal recessive hypophosphatemic rickets (ARHR) in humans (3,20-
23,57), which is similar to that found in Dmp1-null mice (3). Additionally it is known 
that DMP1 must be cleaved to the NH2-terminal and COOH-terminal fragments, among 
which the C-terminal appears to be a key functional domain of DMP1 (25,30,47,58,59).  
DMP1 has been considered as an extracellular matrix (ECM) protein since its 
discovery. An early in vitro mechanism study showed that DMP1 facilitates the 
biomineralization of collagen fibers and the crystal growth (60). Although the 
phosphorylated bovine DMP1 expressed in marrow stromal cells showed an inhibitory 
effect on hydroxylapatite formation and growth (61), however, these authors also 
showed that the recombinant full-length non-phosphated DMP1 and the phosphated C-
terminal work as the hydroxylapatite nucleator. Furthermore, studies found in the C-
terminal of DMP1 there is a RGD motif, which can bind to the integrin receptors. Based 
on this structure, Wu et al. (35), Eapen et al. (36) and our lab (34) carried out different 
kinds of mechanistic studies, and each of these studies independently demonstrated that 
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DMP1 activates the MAP kinase signaling pathway using the full-length or the C-
terminal fragment of recombinant DMP1 in different mesenchymal cell lines, including 
osteoblast cell lines. All of these groups concluded that DMP1 functions as an 
extracellular matrix (ECM) protein and controls cell function via the αvβ3-integrin-MAP 
kinase signaling pathway. 
Recently, a prevailing theory suggests it has dual functional roles that, in addition 
to functions as ECM protein during biomineralization, it also works as a transcription 
factor in osteoblast and odontoblast. This transcription factor theory of DMP1 is mainly 
based on two lines of evidence: there is a functional NLS sequence in the C-terminal of 
DMP1 which enables its role as a transcription factor that regulates the in vitro 
osteoblast and odontoblast function (37);  the N-terminal of DMP1 can specifically bind 
to the glucose-regulated protein-78 (GRP-78) receptor on the cell membrane and then 
triggers the internalization of full-length DMP1 via the endocytosis process (39). In 
addition, two laboratories showed evidence of DMP1 in the nucleus both in vivo (based 
on the immunostaining images) (62) and in vitro [DMP1 in the cell (38)]. Briefly, DMP1 
is first internalized and transported into the nucleus to function as a transcription factor 
in osteoblasts, and later DMP1 gets phosphorylation in the nuclei, which triggers its 
exportation in to the matrix where it initiates the nucleation of hydroxyapatite formation 
and promotes the maturation and differentiation of osteoblasts/osteocytes (37).   
However, this dual function theory is debatable. It was challenged by the 
identification of a DMP1 mutation in several ARHR patients, named as Met1Val (M1V) 
mutation, which had a biallelic nucleotide substitution in DMP1 start codon (ATG to 
GTG, or A1→G). This mutation resulted in the disruption of the ER signal sequence in 
DMP1 (3), since Farrow and coworkers transfected the construct of M1V DMP1 into 
UMR-106 cells (osteosarcoma-derived cell lines) and demonstrated that the M1V DMP1 
did not move to the trans-Golgi network for secretion, instead, it filled the entire 
cytoplasm (57), suggesting DMP1 may mainly function as a ECM protein. Furthermore, 
Kucka and coworkers (52) reported that gonadotropin-releasing (GnRH) hormone 
induces a 600-fold increase in the Dmp1 expression in the primary pituitary cells of 
 16 
 
cycling female rats, and a 30-fold increase in Dmp1 expression in the male pituitary 
cells. Their Western blot data clearly revealed a DMP1 signal in the medium of female 
pituitary cells after GnRH treatment, while no DMP1 signal was identified in the lysate, 
indicating DMP1 had been secreted after GnRH induction and little was internalized. In 
addition, the immunohistochemistry studies by Kucku et al. (8) showed DMP1 in the 
cytoplasm but not in the nucleus, and the co-localization of DMP1 with other secreted 
hormones (such as FSHβ) further supported the theory that DMP1 is a secreted ECM 
protein rather than a nuclear protein.  
To further explore the role of DMP1 in bone biology, we firstly identified the 
expression of DMP1 in postnatal osteoblasts and osteocytes, and its role in regulating 
osteoblasts in vivo. We further generated two constructs, which either carried its original 
endoplasmic reticulum (ER)-entry signal sequence of DMP1 (referred to as SPDMP1) or 
replace this secretory signal sequence with NLS sequence (referred to as NLSDMP1). 
Results of in vitro cell transfection showing the similar regulation of these two 
constructs -- there are up-regulated mRNA levels of bone sialoprotein (Bsp) and alkaline 
phosphatase (Alp). However, the expression levels of osteopontin (Opn), osteocalcin 
(Ocn), dentin sialophos-phoprotein (Dspp), and sclerostin (Sost) were significantly 
reduced. However, evaluations of in vivo transgenic mice models revealed contrary 
results -- NLSDMP failed to rescue Dmp1-null phenotype, whereas SPDMP1 successfully 
reversed the defects. These findings suggest that 1) the transcription factor hypothesis 
based on the in vitro data may reflect a non-physiological event in an extremely high 
concentration, and 2) DMP1 mainly functions as an ECM protein during postnatal bone 
development.  
 
Experimental Procedure 
Adenovirus constructs  
The full-length murine Dmp1 cDNA was cloned into an adenovirus CMV 
construct (Ad-CMV victor) by Baylor College of Medicine (Vector Development Lab) 
with the endogenous signal peptide (MKTVILLVFLWGLSCAL, SPDMP1) or with its 
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signal peptide replaced by a nuclear localization signal peptide (PPKKKRKV, 
NLSDMP1).  
 
Cell culture and adenovirus infection 
MC3T3 cells were cultured in a 12-well plate with α-modified Eagle’s medium 
(α-MEM) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). 
Infection was performed when the cells reached at least an 80% confluence level. 
Vectors in α-MEM with a concentration of 1X109 viral particles/well was added, and 
then incubated in a CO2 incubator for 30 min before adding the culture medium. The 
infection efficiencies were tested under a fluorescent microscope, which showed the 
highest efficiencies after 48 hours. All the cells were cultured at 37°C in a humidified 
5% CO2 atmosphere. 
 
Quantitative real-time PCR 
Total RNA was extracted from the infected MC3T3 cells using Trizol reagent 
(Invitrogen, San Diego, CA, USA) according to the manufacturer’s protocol, then 
reverse-transcribed into cDNA, followed by real-time PCR analysis, as in our previous 
studies (16). The genes analyzed included Dmp1, Bsp, Alp, Opn, Ocn, Dspp, and Sost 
with GAPDH as an internal control. The details of the primer sequences were as follows: 
the Dmp1 forward primer, 5’- AGT GAG TCA TCA GAA GAA AGT CAA GC-3’, and 
reverse primer, 5’- CTA TAC TGG CCT CTG TCG TAG CC-3’; Bsp forward primer, 
5’-GAG ACG GCG ATA GTT CC-3’, and reverse primer, 5’-AGT GCC GCT AAC 
TCA A-3’;  Alp forward primer, 5’-CTT GCT GGT GGA AGG AGG CAG G-3’, and 
reverse primer, 5’-CAC GTC TTC TCC ACC GTG GGT C-3’; Opn forward primer, 5’-
TTT ACA GCC TGC ACC C-3’, and reverse primer, 5’-CTA GCA GTG ACG GTC T-
3’; Ocn forward primer, 5’-CTC TGT CTC TCT GAC CTC ACA G-3’, and reverse 
primer, 5’-GGA GCT GCT GTG ACA TCC ATA C-3’; Dspp forward primer, 5’-AAC 
TCT GTG GCT GTG CCT CT-3’, and reverse primer, 5’-TAT TGA CTC GGA GCC 
ATT CC -3’; Sost forward primer, 5’-AGC TCC TTC AGA GGG CTG AT-3’, and 
 18 
 
reverse primer, 5’-GAG GCA GGC ATT TCA GTA GC-3’; and GAPDH forward 
primer, 5’-GGT GTG AAC CAC GAG AAA-3’, and reverse primer, 5’-TGA AGT CGC 
AGG AGA CAA-3’. 
 
Generation and characterization of the NLSDmp1 transgenic mice  
To generate the Col1α1-NLSDmp1 transgene, the full-length mouse Dmp1 cDNA 
with its ER-entry signal sequence replaced by a nuclear localization signal (NLS) 
sequence, and a SV40 polyadenylation signal sequence were cloned into a mammalian 
expression vector (63) (graciously provided by B. Kream and A. Lichtler, University of 
Connecticut Health Center, Farmington, CT, USA) containing the 3.6-kb rat type 1 
collagen promoter plus a 1.6-kb intron 1 at the EcoRV and SalI sites, which give rise to 
the Col1α1-NLSDmp1 transgene. This transgene was released from the vector backbone 
by SacII and SalI, then purified for pronuclear injection. Transgenic founders with a 
C57B/L6 background were generated at the UT Southwestern Medical Center (Dallas, 
TX, USA). A total of nine independent transgenic lines were obtained and partially 
characterized by radiographs, µCT and H&E stain. Except for one line displaying an 
increase in femur trabecular bone volume, the rest of the transgenic mouse lines showed 
no apparent differences from the control mice (data not shown). Three independent lines, 
including the line with a high trabecular bone volume, were crossed to Dmp1-null mice 
for in-depth rescue studies (see Table 2-1).  
 
Target expression of the NLSDmp1 transgene into the Dmp1-null mice  
The Dmp1-null mice with a C57B/L6 genetic background using the lacZ knock-
in target approach were described previously (28). To target Dmp1 in the nucleus, the 
Dmp1-null mice were crossed with 3 different NLSDMP1 lines with line #95 (whose 
expression level is 6-fold higher than that of the WT Dmp1) for a full characterization 
using multiple approaches. Since no apparent phenotypic differences between the wild 
type (WT) and heterozygous (Het) Dmp1 mice were found, the Het Dmp1 mice were 
used as controls. All of the mice were fed with autoclaved Purina rodent chow (Ralston 
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Purina, St. Louis, MO, USA) containing 1% calcium, 0.67% phosphorus, and 4.4 IU of 
vitamin D/g. All the animal procedures were performed in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by 
the Institutional Animal Care and Use Committee of Texas A&M Baylor College of 
Dentistry. 
 
PCR genotyping 
Genomic DNA was extracted from a tail biopsy and used for genotyping by PCR 
analysis. Primers p01 (5’-GAG TGC GAT CTT CCT GAG GCC GAT ACT GTC-3’) 
and p02 (5’-CGC GGC TGA AAT CAT CAT TAA AGC GAG TGG-3’) were used for 
targeting LaccZ (490 bp); primers p03 (5’-GCC CCT GGA CAC TGA CCA TAG C-3’) 
and p04 (5’-CTG TTC CTC ACT CTC ACT GTC C-3’) were used for identification of 
endogenous Dmp1 (400bp); primers p05 (5’-CAG CCG TTC TGA GGA AGA CAG 
TG-3’ from Dmp1 cDNA) and p06 (5'-TGT CCA AAC TCA TCA ATG TAT CT-3’ 
from the SV40 polyadenylation signal) were used to detect the transgenic NLSDMP1 (337 
bp), respectively. 
 
Protein extract and western blot 
To determine whether the NLSDMP1 was expressed in the bone cells, total cell 
lysates were extracted from the HET and Dmp1-null primary calvarial cells with and 
without the transgene. The concentration of cell lysis was determined with the BCA kit 
(Pierce, Rockford, IL, USA). Ten µg of the total proteins of each group were then 
subjected to 10% DS-PAGE gel, followed by blotting onto a polyvinylidene difluoride 
membrane. The membranes were subsequently immunoblotted with the anti-DMP1-C-
terminal antibody (47) at the concentration level of 0.2 µg IgG/ml. Alkaline 
phosphatase-conjugated anti-rabbit IgG (Sigma-Aldrich, St. Louis, MO, USA) was 
employed at a dilution of 1:5000 as the secondary antibody. Following this procedure, 
the membranes were incubated in chemiluminescent substrate CDP-star (Ambion, Grand 
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Island, NY, USA) for 5 min and exposed to Kodak film (Perkin Elmer, Waltham MA, 
USA) to visualize the bands. 
 
Histology 
For the decalcified bone analysis, the animals were injected twice with 5-Bromo-
2’-deoxyuridine (BrdU, 100 ug/g mouse, i.p.; Sigma-Aldrich, St. Louis, MO, USA). The 
first injection of BrdU was made after 24 hours, and the second was 2 hours before the 
mouse was sacrificed). For fixation, perfusion was performed using freshly prepared 4% 
paraformaldehyde in phosphate-buffered saline (pH 7.4). Next, the specimens were 
decalcified and embedded in paraffin, as described previously (7). Sections were cut in 
4.5 µm slices, mounted on slides and dried. These slides were used for 
immunohistochemistry, Hematoxylin & Eosin (HE), safranin-O, TRAP, and BrdU 
staining (BrdU staining kit, Invitrogen, Grand Island, NY, USA), as previously reported 
(3). The antibodies used for the immunohistochemistry were listed as the following: anti-
DMP1-C-terminal polyclonal antibody (59), anti-E11 antibody (64), anti-sclerostin 
polyclonal antibody (R&D Biosystems, Minneapolis, MN, USA), and anti-osterix 
monoclonal antibody (Abcam, Cambridge, MA, USA) and anti-decorin monoclonal 
antibody (65). For the undecalcified bones, the specimens were dehydrated in ascending 
concentrations of ethanol (from 70% to 100%) and embedded in methyl methycrylate 
(MMA, Buehler, Lake Bluff, IL), then cut in 6-mm-thick slices using a Leica 2165 
rotary microtome (Ernst Leitz Wetzlar). The undecalcified specimens or sections were 
stained by Masson goldner trichrome staining (3), Von Kossa staining and Alizarin 
red/alcian blue staining (28). 
 
β-Galactosidase (lacZ) expression assay  
The method of β-Galactosidase staining was described previously (17). The fresh 
fixed 3-week-old heterozygous mouse long bone was rinsed with phosphate-buffered 
saline after 15 min fixation, and then the specimens were stained for 48 hours in freshly 
prepared X-gal solution (1mg/ml) at 37 °C. The stained samples were washed with 
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phosphate-buffered saline again, followed by re-fixation, decalcification, and embedded 
in paraffin for sectioning and counterstaining.  
 
High-resolution radiography, microcomputed tomography (µCT) and scanning 
electron microscopy (SEM) 
After the muscle tissue was removed, radiographs of the bone specimens were 
taken using a Faxitron model MX-20 Specimen Radiography System with a digital 
camera (Faxitron X-Ray Corp., Lincolnshire, IL, USA). Long bone µCT analyses were 
performed using the Scanco µCT35 (µCT35; Scanco Medical, Bassersdorf, 
Switzerland). By means of serial tomographic imaging at an energy level of 55 kV and 
intensity of 145 µA, the cortical thickness data were obtained at the midshaft of the 
bone. Thus, 100 cross sections of slices above the midshaft of the femur were analyzed 
at the threshold of 283. The MMA-embedded samples were cut and the surfaces 
polished using 1 µm and 0.3 µm alumina alpha micropolish II solution (Buehler), 
followed by acid etching with 37% phosphoric acid for 2 to 10 seconds, 5% sodium 
hydrochloride for 5 minutes and then gold-coated with gold and palladium. The 
specimens were scanned by a FEI/Philips XL30 field-emission environmental SEM 
(Hillsboro, OR, USA), as described previously (25). 
 
Serum biochemistry  
A common cardiac puncture method was used to collect blood from the 6-week-
old mice under anesthesia. The serum phosphorus was measured using the 
phosphomolybdate–ascorbic acid method, and the serum FGF23 level was determined 
with a full-length FGF23 ELISA kit (Kainos Laboratories, Tokyo, Japan), as previously 
described (3). 
 
Statistical analysis 
The data analysis was performed with a one-way ANOVA for multiple-group 
comparison. If significant differences were found with the one-way ANOVA, the 
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Bonferroni method was used to determine which groups were significantly different 
from the others. The quantified results are represented as the mean ± standard error of 
the mean (SE). We considered P<.05 as the statistical significance level. 
 
Results 
Identify the expression and function of DMP1 in osteoblasts in vivo 
DMP1 was previously reported having in vivo biological functions mainly related 
to its expression in osteocytes during postnatal development (8,9,28). Recent in vitro 
studies also suggested DMP1 may also be expressed in the osteoblasts to regulate their 
function (62,66). To further identify the expression of DMP1 in vivo, we studied the 
postnatal Dmp1 expression profile using the x-gal staining approach, in which the lacZ 
signal reflects endogenous Dmp1 since the lacZ reporter is used to replace exon 6 of 
Dmp1 (17). Different stages of Dmp1-HET bones were used for this study, and we not 
only confirmed that the Dmp1-lacZ signal is mainly expressed in the osteoblast at E16.5 
(Fig. 2-1, a, insert), but also identified a strong Dmp1-lacZ signal in both osteocytes 
(Fig. 2-1, a, left) and osteoblasts, with abundant blue osteoblasts in the metaphysis 
region of 3 week-old mice (Fig. 2-1, a). 
To test the role of DMP1 in osteoblast in vivo, we then re-examined the 
phenotype of the ectopic bone mass in the Dmp1-null metaphysis (Fig. 2-1, b). The 
safranin O stain images showed a lack of cartilage residue in the Dmp1-null metaphysis 
(Fig. 2-1, c), compared to the control trabeculae, in which there were numerous cartilage 
remnants (Fig. 2-1, c). However, the mineralization in these expanded Dmp1-null 
metaphyses was poor, based on the von Kossa stain images (Fig. 2-1, d). Besides, there 
were increased mesenchymal-derived cells in the Dmp1-null metaphysic as found by 
toluidine staining (Fig. 2-1, e). We also evaluated the molecular changes in the Dmp1-
null metaphysis and documented high levels of BrdU, Runx2, parathyroid receptor 
(Pthr), and OSX compared to the control (Figs. 2-1, f-i). These results support the theory 
that, in addition to its role in osteocytes, DMP1 also regulates osteoblasts by slowing 
down cell proliferation and accelerating cell differentiation.  
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The overexpression of SPDMP1 or NLSDMP1 greatly changed the osteoblast activities 
in vitro in a similar manner 
One of ways to test the dual function of DMP1 (as an ECM protein and a 
transcription factor) is generating two different forms of DMP1 to ensure its different 
subcellular localizations: SPDMP1, the secreted DMP1 form containing its own 
endoplasmic reticulum (ER) entry signal sequence, and NLSDMP1, the endogenous ER 
entry signal sequence was replaced by a nuclear localization signal sequence to ensure 
the nuclear localization of DMP1, using the adenovirus CMV (Ad-CMV) approach (Fig. 
2-2, a, left). Both constructs, plus an empty Ad-CMV construct (as a control), were used 
to infect MC3T3 (a pre-osteoblast cell line) for 48 hours. Quantitative real-time PCR 
was then performed to examine the mRNA expression levels of the targeted Dmp1 in the 
infected cells. As expected, there was significantly higher expression of Dmp1 mRNAs 
in both forms, compared to the control (Fig. 2-2, a, right; Table 2-2). Further analyses of 
the common markers linked to mineralization revealed an identical response pattern in 
both experimental groups compared to the control. For example, Bsp and Alp sharply 
increased, whereas Ocn, Opn, Dspp and Sost were significantly reduced in both infected 
groups (Figs. 2-2, b; Table 2-2). These findings indicated that the NLSDMP1 transgene 
exhibits the same biological response as that of the SPDMP1 when highly expressed in 
vitro, in agreement with a previous report (37). 
 
Specifically targeting DMP1 in the nuclei of osteoblasts and osteocytes or secreting it 
into the matrix  
To test the in vivo function of both the NLSDMP1 and SPDMP1 transgenes, we 
generated transgenic mice containing these transgenes in the osteoblasts and osteocytes 
using a 3.6 kb Col 1α1 promoter (Fig. 2-3, a). Three independent lines among nine 
partially characterized lines of NLSDMP1 transgenic mice (see Table. 2-1) were crossed 
to the Dmp1-null mice separately, with line #2095 being fully characterized. The 
immunohistochemistry revealed that in the Dmp1-HET control, endogenous DMP1 was 
expressed in the bone matrices surrounding the osteocyte and its dendrites with little 
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signal found in the nuclei (Fig. 2-3, c), whereas in the NLSDMP1 transgenic mouse with 
the HET background, DMP1 was detected in both the bone matrix (the endogenous) and 
the nuclei (the transgene) of the osteoblasts and osteocytes (Fig. 2-3, c, arrows). As 
anticipated, there was no positive signal in the Dmp1-null bone matrix, whereas the 
NLSDMP1 was highly expressed in the nuclei of osteoblasts and osteocytes but not in the 
bone matrix, compared to a expression in matrix and cytoplasm of DMP1 in the 
KO+SPDMP1 group (Fig. 2-3, c). The Western blot of the cell lysates from the primary 
calvarial cells further confirmed a high level of NLSDMP1 with a size of 115-KDa in the 
cell lysate of both HET and KO animals with NLSDMP1 transgene (Fig. 2-3, b). 
 
The Dmp1-null mice displayed hypophosphatemic rickets whith high levels of cell 
proliferation in the prehypertrophic zone was rescued by SPDMP1 but not NLSDMP1  
The key Dmp1-null phenotype is short limbs due to a defect in endochondral 
bone formation. In this study, we asked whether overexpression of the NLSDMP1 
transgene accelerates skeleton growth in the WT background. Interestingly, none of the 
three lines tested showed an apparent change in skeleton length and size except that 
there was an increase in the trabecular bone volume in the bone marrow was observed in 
line #2095 (Fig. 2-5, b), similar to our previous report that adding the SPDMP1 transgene 
in the WT background does not accelerate in vivo skeleton formation or mineralization 
(25). 
We previously demonstrated that the short stature of the Dmp1-null mice was 
secondary to the hypophosphatemia caused by the elevated FGF23 (3). This heightened 
FGF23 decreased Pi levels, which inhibited cell apoptosis in the hypertrophic 
chondrocytes (67), leading to a sharp reduction in bone growth with severe skeleton 
deformities (18). We hypothesized if DMP1 functioned as a transcription factor, their 
subcellular activity could rescue the abnormal serum FGF23 concentration. Our results 
suggested matrix DMP1 may be the key factor since SPDMP1 fully normalized the serum 
levels of FGF23 and Pi at the age of 6 weeks; whereas, NLSDMP1 failed to correct this 
affected serum biochemical changes (Figs. 2-4, a-b). We also compared the x-ray images 
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of mice at the ages of 3 weeks, 6 weeks and 1 year and attempted to determine which 
form of DMP1 may correct the remodeling defect in the Dmp1-KO mice, as many 
phenotypes are linked to the bone remodeling process and it becomes worse with age 
(18). Again, the representative radiographs (Fig. 2-4, e) demonstrated no apparent 
improvement in the KO+NLSDMP1 animals, but the KO+SPDMP1 group appeared to be 
rescued. 
Unexpectedly, we also identified an expansion of the proliferating zone in the 
Dmp1-null mice with or without expression of NLSDMP1 using Safranin O stain, an 
abnormity we and others hadn’t systematically reported previously (Fig. 2-4, f). The 
BrdU images showed high levels of cell proliferation in the KO growth plate (Fig. 2-4, 
g). The quantitation data confirmed that these new findings have significantly different 
between the control and the KO groups (Figs. 2-4, c-d). However these abnormalities 
were greatly rescued after re-expression of SPDMP1 as the figures and charts showed 
(Figs. 2-4, c-g). Our further analysis indicated several molecular markers important for 
chondrocyte differentiation greatly increased in the null chondrocytes, including Runx2 
(Fig. 2-4, h, in situ), sonic hedgehog (Shh, Fig. 2-4, i, in situ), SOX9 (Fig. 2-4, j, IHC), 
and osterix (OSX, Fig. 2-4, k, IHC) (68). As a whole, we demonstrated an up-regulation 
of chondrocyte proliferatiion and their function in the proliferating zone of Dmp1-null 
growth plate, which contributed to the expanded growth plate in the Dmp1-null mice. 
Meanwhile, we found that the NLSDmp1 transgene in the null osteoblast-osteocyte had no 
apparent rescue effect on the rickets phenotype but SPDMP1 did. 
 
Expression of SPDMP1 in osteoblasts-osteocytes had an apparent rescue effect on 
mineralization while expression of NLSDMP1 did not 
To test whether the NLSDMP1 or the SPDMP1 rescues mineralization defects, we 
stained bone (using Alizarin red) and cartilage (with alcian blue). The deformed skeleton 
in the Dmp1-null mice was essentially the same as it in KO+NLSDMP1 group (Fig. 2-5, 
a), on the contrary, bone in the KO+SPDMP1 was as normal as the HET controls (Fig. 2-
5, a). Further µ-CT analysis displayed porous cortical bone in the KO and KO+NLSDMP1 
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cross sectioned images (Fig. 2-5, b), and statistical analyses of bone histomorphometry 
showed significant changes compared to the age-matched HET and KO+ SPDMP1 
groups (Table 2-3). Additionally, the Goldner stain images (Fig. 2-5, c) also revealed no 
apparent rescue effect on the osteomalacia phenotype in KO+ NLSDMP1 group. 
Interestingly, the expression of SPDMP1 led to an almost full rescue of these deficiencies 
(Figs. 2-5, a-c). 
Previously we reported that the mineralization defect in the Dmp1-null mice was 
directly linked to the pathological changes in the osteocyte morphologies, including an 
enlarged cell body and reduction of the dendrite number (16,69). In this study, we re-
analyzed the SEM image data and found great improvement of cell morphology after re-
expression of SPDMP1 in Dmp1-null mouse but not in the KO+NLSDMP1 mouse (Fig. 2-
5, d), indicating that secreting DMP1 into the matrix is important for the osteocyte 
morphologies or functions. In accordance, analyses of mineralization-related markers 
indicated the secreted DMP1 but not the nuclear targeted DMP1 restored the expression 
pattern of 1) decorin (Fig. 2-6, a, an inhibitory factor for mineralization); 2) OSX (Fig. 
2-6, b, a critical transcription factor for osteoblast function); 3) E11/gp38 (Fig. 2-6, c, 
E11, a marker linked to the newly formed osteocytes or immature osteocytes), or 4) 
sclerostin (Fig. 2-6, d, SOST, an inhibitory matrix protein against Wnt/β-catenin 
signaling, mainly expressed in the mature osteocytes). Collectively, the overexpression 
of the NLSDMP1 in the null osteoblast and osteocyte failed to rescue osteomalacia, which 
challenges the dual-function hypothesis.  
 
Discussion  
DMP1, a key molecule controlling osteocyte function (3) and bone remodeling 
(70), also plays critical roles in many tissues such as cartilage, kidney, body balance, 
salivary, pituitary, and blood vessels (6,7,12,13,49-52). Moreover, in this report, we 
identified DMP1 expression in osteoblasts and its regulation of osteoblast 
proliferation/differentiation in vivo. Recent studies suggested it might also have dual 
function (as a transcription factor and an ECM protein) in osteogenesis (37,39). 
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However, the conclusion from our study did not support the hypothesis that the full-
length DMP1 could act as a transcription factor, instead, the matrix expression of DMP1 
had a more crucial role in bone biology. 
The controversy in this study is that our in vitro study suggested DMP1 may 
function as a transcription factor in regulating osteoblasts, however, the in vivo study 
didn’t agree with this data. Instead, the in vivo data indicated secreted DMP1 plays a 
more important role, since the NLSDMP1 failed to rescue the rachitic phenotype in 
Dmp1-null mice but SPDMP1 transgene did. Therefore, we propose that the dual-
function hypothesis may reflect a non-physiological phenomenon in an extremely high 
in vitro concentration, and DMP1 actually does function as an ECM protein in both 
osteoblasts and osteocytes during postnatal development. Furthermore, this difference 
may be related to the variance between in vivo and in vitro studies. Generally, in vivo 
studies are more complicated and sometimes even lead to different conclusions when the 
results are compared to in vitro findings. For example in vivo cell growth is three-
dimensional and affected by both local and systemic factors, especially the osteogenic 
cells, which are also significantly influenced by biomechanical stimulation (71).  
We previously generated the SPDMP1 transgene, which was driven by the 3.6 kb 
Col 1α1 promoter (highly active in osteoblasts and osteocytes); however, it did not have 
an apparent effect on the WT mice but fully rescued the Dmp1-null mice (25,30,72), 
suggesting that the dosage effect of DMP1 in vivo is limited although it is essential for 
postnatal skeleton and tooth formation. As a result, the same approach and promoter 
were used to generate NLSDMP1 mouse lines in this study. However, line #2095 of 
NLSDMP1 transgenic mice displayed an ectopic trabecular bone formation (Fig. 2-5, b). 
Thus, we also evaluated another line (#2097) (Fig. 2-7) and their offspring displayed no 
extra bone formation, compared to line #2095. These results suggest the extra bone 
formation in the line #2095 was more likely resulted from the processes or the 
operations conducted during the generation of this transgenic line rather than a 
functional role of nuclear activities of DMP1.  
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The previous work of DMP1 was mainly focused on its role in osteocytes, since 
DMP1 is highly expressed in the osteocytes during postnatal development (8,9,28), In 
this work, we showed the continuous expression of a high level of Dmp1-lacZ in 
osteoblasts in the metaphysis during early postnatal development (Fig. 2-1, a). 
Furthermore, we demonstrated that the deletion of Dmp1 leads to the acceleration of 
bone cell proliferation (from BrdU analysis) and osteoblast differentiation (from 
expression of Runx2, parathyroid receptor, and OSX) compared to the control, resulting 
in an expanded metaphysis, although the mineralization was poor (Fig. 2-1). In addition, 
the re-expression of DMP1 rescued the metaphysis phenotype (Fig. 2-4, e) (25,30) and 
the differentiation of osteoblasts (Figs. 2-6, a-d), supporting the novel role of DMP1 in 
osteoblasts (reducing osteoblast cell proliferation and accelerating the differentiation of 
osteoblasts into osteocytes). 
Recent mechanistic studies suggest DMP1 is first internalized by the 
osteoblast/odontoblast via GRP-78-mediated endocytosis and works as a transcription 
factor in the nucleus to regulate the expression of osteoblast-/odontoblast-specific genes. 
Later during osteoblast maturation, DMP1 is phosphorylated in the nucleus, then 
exported into the matrix where it acts as an ECM molecule to regulate biomineralization 
(37,39). However, our current findings suggest that it was unlikely for the nuclear DMP1 
to be transported out and secreted into the ECM during osteogenesis. First of all, both 
our ex vivo and in vivo analysis of NLSDMP1 showed there was no detectable DMP1 in 
the culture medium and bone matrix after its transportation in the nucleus. Besides, if the 
nuclear DMP1 can be exported into the ECM, we would expect that NLSDMP1 can at 
least partially rescue the defects of Dmp1-null mice; however, none of the 
KO+NLSDMP1 mice showed rescue. Moreover, the M1V mutant DMP1 is presumed to 
enter the nuclei, since only the secretory sequence was interrupted but the NLS in the C-
terminal still made function (3,37). In accordance with the results observed from mouse 
model, the ARHR patient with a M1V mutation had typical rachitic symptoms (3). 
Additionally, another transgenic DMP1 with mutations in D213 that only lead to the 
unsuccessful traditional processing of DMP1 but no influence in the other domains 
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including the secretory sequence and the NLS sequence, also failed to rescue the rachitic 
phenotype of Dmp1-null mice (47,73,74). In addition, we previously reported that the C-
terminal fragment of DMP1 was sufficient to completely rescue the Dmp1-null mouse 
skeletal and dental abnormalities (25,30). 
In summary, the in vitro over-expression of SPDMP1 (the secreted form) or 
NLSDMP1 (the nuclear form) greatly changed osteoblast differentiation in an identical 
manner. However, in vivo studies using genetic rescue approaches to target DMP1 either 
in the Dmp1-null nucleus or in the null extracellular matrix demonstrate that DMP1 
functions as an ECM protein, rather than as a transcription factor, which challenges the 
dual-function theory. Based on new findings and the publications from our lab and 
others (18,34,35), we propose that DMP1 is secreted into the extracellular matrix (Fig. 2-
8, a), where this ECM molecule binds to αvβ3 integrin, leading to activation of the MAP 
kinase signaling pathway in the cell. The deletion of Dmp1 results in two novel 
phenotypes: 1) an increase in osteoblast cell proliferation, along with an inhibition in 
osteoblast differentiation into osteocytes, which causes abundant, but poorly mineralized 
intramembranous bone formation in the metaphysis (reflecting the direct role of DMP1 
in osteoblasts); and 2) an increase in prechondrocyte activity (an indirect role likely due 
to hypophosphatemia) (Fig. 2-8, b).  
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CHAPTER III 
NUCLEUS-TARGETED DMP1 FAILS TO RESCUE DENTAL DEFECTS IN DMP1 
NULL MICE 
 
Synopsis 
Dentin Matrix Protein 1 (DMP1) is essential in odontogenesis. In this study, we 
examined whether full-length DMP1 could function as a transcription factor in the 
nucleus and regulate odontogenesis. We first demonstrated that a patient with the DMP1 
M1V mutation, which presumably causes a loss of the secretory DMP1 but does not 
affect the nuclear translocation of DMP1, shows a typical rachitic tooth defect. 
Furthermore, we generated a transgenic mouse in which the endoplasmic reticulum (ER) 
entry signal sequence of DMP1 was replaced by a nuclear localization signal (NLS) 
sequence (referred to as “NLSDMP1”). Although the NLSDMP1 was localized in the 
nuclei of the preodontoblasts and odontoblasts, we found that it failed to rescue the 
dental and periodontal defects as well as the delayed tooth eruption in Dmp1-null mice.  
We concluded that the full-length DMP1 plays no apparent role in the nuclei in 
odontogenesis. 
 
Introduction 
Dentin Matrix Protein 1 (DMP1), a member of the small integrin-binding ligand 
N-linked glycoprotein (SIBLINGs) family (55), plays essential roles in osteogenesis and 
odontogenesis. DMP1 mutations in humans and its deletion in mice result in autosomal 
recessive hypophosphatemic rickets (ARHR), characterizing by rickets/osteomalacia, 
hypophosphatemia, and elevated circulating fibroblast growth factor 23 (FGF23) (3). 
The teeth of Dmp1-null mice display enlarged pulp cavities and root canals, increased 
thickness of the predentin zone with a reduced dentin wall, hypomineralization of dentin, 
abnormalities in the ultrastructure of dentinal tubules, delayed development of the third 
molar, breakdown of periodontal structures, and other consequences (17,34,72,75). 
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Several lines of evidence support the finding that DMP1 acts as an extracellular 
matrix (ECM) protein. First, the initial 16 amino acid residues of DMP1 deduced from 
its cDNA is a typical endoplasmic reticulum (ER) signal sequence, and this protein is 
found abundantly in the matrix (28,48). Second, the DMP1 protein sequence contains 
some specific acidic clusters that control the formation of oriented calcium phosphate 
crystals (7,31). Gajjeraman and others further confirmed that both the full-length DMP1 
and the COOH-terminal fragment could accelerate the nucleation of hydroxyapatite 
crystals (32,33,61). Lastly, studies from our lab and others demonstrated that DMP1 has 
the ability to activate the extracellular signal-regulated kinase (ERK)-mitogen-activated 
protein kinase (MAPK) pathways via the αvβ3 integrin, leading to the translocation of 
phosphorylated JNK into the nucleus and the concomitant up-regulation of 
transcriptional activation by phosphorylated c-Jun (34-36). 
However, in vitro studies indicated that DMP1 also might function as a 
transcription factor in the nucleus. George et al. first reported that the DMP1 protein 
sequence contained a functional nuclear localization signal (NLS) sequence, which was 
thought to be responsible for the nuclear import of full-length DMP1 in pre-odontoblast-
like cells (37). They further demonstrated that the extracellular full-length DMP1 could 
be internalized via endocytosis mediated by glucose-regulated protein-78 (GRP-78), an 
endoplasmic reticulum (ER) chaperone protein found on the plasma membrane of 
preodontoblasts and subsequently transported into the nucleus. Once in the nucleus, 
DMP1 regulates the transcription of odontoblast-specific genes such as DSPP (37,39). 
These investigators proposed that during the maturation of the pre-
odontoblast/odontoblast, this nuclear DMP1 would be phosphorylated by casein kinase 
II, leading to its exportation into the extracellular matrix where it promotes 
hydroxyapatite formation (37). However, the role of nuclear DMP1 has been challenged 
by the identification of several patients who presumably have normal nuclear 
localization of DMP1 due to a biallelic nucleotide substitution in the DMP1 start codon 
(ATG to GTG, or A1→G), but who display hypophosphatemic rickets (3). Therefore, 
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whether DMP1 can enter the nucleus and function as a transcription factor in vivo 
needed to be studied further.  
This study was aimed at determining the nuclear DMP1 in odontogenesis had an 
in vivo function. Our human studies revealed that an ARHR patient, with a M1V 
mutation at the DMP1 start codon, manifested typical rachitic dental defects. Animal 
studies showed that the targeted expression of NLSDMP1 in the Dmp1-null nucleus failed 
to rescue the Dmp1-null dental defects, suggesting that DMP1 plays no apparent role in 
the nuclei during odontogenesis.  
 
Materials and Methods  
Human subjects 
The study protocol and patient consents were reviewed and approved by the 
Institutional Review Boards at the University of Ottawa. Dental radiographs were 
obtained from the previously described individual (3).  
 
Generation of Col1α1-NLSDMP1 transgenic mice  
For the generation of the Col1α1-NLSDMP1 transgene, the full-length mouse 
Dmp1 cDNA with its ER-entry signal sequence (30) replaced by an NLS sequence 
(NLSDMP1). Together with a SV40 polyadenylation signal, the NLS sequence was 
cloned into the EcoR V and Sal I sites of a mammalian expression vector (63) 
downstream of the 3.6 kb rat type I collagen promoter plus a 1.6 kb intron 1. The 
Col1α1-NLSDMP1 transgene was then released from the vector backbone by Sac II and 
Sal I and purified for pronuclear injection. Transgenic founders with a C57B/L6 
background were generated at the UT Southwestern Medical Center, Dallas, TX, USA. 
Genotyping was conducted as previously (34,72).  
 
Targeted expression of the NLSDMP1 in Dmp1-null mice  
Three of five independent transgenic lines were separately crossed with Dmp1-
null (Dmp1-/-) mice to introduce the Col1α1-NLSDMP1 transgene into the Dmp1-/- mice 
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(referred to as “Dmp1-/-; Col1α1-NLSDMP1”). All three transgenic lines had similar 
rescue effects on the Dmp1-null dental defects, so only the data obtained from line #95 
are presented. The littermate Dmp1-heterozygous (Dmp1+/-) mice were used as control 
mice since there was no phenotypic difference between these Dmp1+/- and wild-type 
(WT) mice. The mice were fed with Purina rodent chow (5010, Ralston Purina, St. 
Louis, MO, USA) containing 1% calcium, 0.67% phosphorus, and 4.4 IU of vitamin 
D/g. All the animal procedures were performed in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by 
the Institutional Animal Care and Use Committee of Texas A&M University Baylor 
College of Dentistry (Dallas, TX, USA). 
 
Histology 
The animals were sacrificed and fixed in freshly made 4% 
paraformaldehyde/PBS (pH 7.4), followed by decalcification and paraffin embedding. 
Sections (4.5 µm) were cut for histochemistry staining and immunohistochemistry 
staining as previously described (3). Toluidine Blue and Sirius Red (also called “Direct 
Red 80”) were obtained from Sigma (Sigma, St. Louis, MO, USA). The antibodies used 
for immunohistochemistry were anti-DMP1-C-terminal polyclonal antibody (59), anti-
DSP monoclonal antibody (76) and anti-Biglycan monoclonal antibody (77).  
 
High-resolution radiography, microcomputed tomography (µ-CT) and resin casted 
scanning electron microscopy (SEM) 
The mouse mandibles were dissected free of muscle. High-resolution radiographs 
were taken using a plain x-ray radiography system (Faxitron MX-20DC12 system, 
Faxitron Bioptics) with a digital camera (Faxitron X-Ray Corp., Lincolnshire, IL, USA). 
µ-CT analysis was performed with the Scanco µCT35 (Scanco Medical, Bassersdorf, 
Switzerland) as described previously (34). For SEM analysis, the samples were 
embedded in methyl methacrylate and cut to expose the dental pulp and root canals; the 
surface was then polished using alumina alpha micropolish II solution (Buehler), acid 
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etched, and then scanned by a FEI/Philips XL30 field-emission environmental SEM 
(Hillsboro, OR, USA) as described previously (25). 
 
Statistical analysis 
Data analysis was performed with one-way ANOVA for multiple-group 
comparison. If significant differences were found with one-way ANOVA, the 
Bonferroni method was used to determine which groups were significantly different 
from others. The quantified results were presented as the mean ± SEM. p<.05 was 
considered statistically significant. 
 
Results 
A patient with a DMP1 M1V mutation displayed deformed teeth  
We previously reported that a DMP1 M1V mutation was identified in an ARHR 
patient (3). The DMP1 in this patient had a start codon mutation (A→G) resulting in the 
substitution of the initial methionine with valine. As a result, there was no signaling 
peptide (Fig. 3-1, a). Further analysis revealed that the M1V mutant DMP1 protein was 
wholly retained within the cells as the 94-kDa full-length DMP1 without cleavage, 
consistent with the change of translational initiation (at an internal methionine) that 
results in the loss of the ER-entry signal peptide (3,57). Dental radiographs (Fig. 3-1, b, 
upper panel) showed enlarged pulp cavities and root canals as well as thinner dentin, 
compared to an age-matched control (Fig. 3-1, b, lower panel). These dental defects 
were very similar to those of other DMP1 mutation kindreds (22) and Dmp1-/-mice 
(17,72). 
 
NLSDMP1 did not rescue the dental defects of Dmp1-/- mice 
To understand whether DMP1 plays a role in the nuclei in vivo, we generated 
Col1α1-NLSDMP1 transgenic mice, which not only mimic the M1V mutation that leads 
to the suppression of its secretion, but also ensure its nuclear transportation by using an 
NLS sequence to replace its ER-entry signal sequence. Three of five independent lines 
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were then crossed with the Dmp1-/- mice to introduce NLSDMP1 into the Dmp1-/- 
background. All three transgenic lines showed a similar phenotype, although only the 
results obtained from line #95 were presented. Immunohistochemistry staining of DMP1 
revealed that in the control Dmp1+/- mice, endogenous DMP1 was detected in the 
dentinal matrix and alveolar bone matrix, as well as the cytoplasm and dendrites of 
odontoblasts (Figs. 3-2, a-c), compared to no signal in the Dmp1-/- mice (Figs. 3-2, a-c). 
Notably, NLSDMP1 was identified in the nuclei, cytoplasm, and dendrites of the 
preodontoblasts and odontoblasts, but not in the dentinal matrix of the Dmp1-/-; Col1α1-
NLSDMP1 mice (Fig. 3-2, a-c).  
Next, a series of experiments were performed to assess whether the targeted 
expression of the NLSDMP1 had rescue effects on the Dmp1-null dental defects. The 
representative radiographs demonstrated that, similar to the Dmp1-/- teeth, the teeth of 
the Dmp1-/-; Col1α1-NLSDMP1 mice teeth displayed significantly thinner dentin and 
shorter roots (Fig. 3-2, d; Figs. 3-7, a-b, P<0.01), enlarged pulp cavities and root canals 
(Fig. 3-2, d). Histological analysis further confirmed that, like the Dmp1-/- mice, the 
Dmp1-/-; Col1α1-NLSDMP1 mice teeth manifested a reduced thickness of the dentin walls 
and an increased thickness of the pre-dentin zone (Figs. 3-3, a-c), indicating there was a 
partial failure of pre-dentin to dentin maturation.  At 6 weeks of age, the expanded pre-
dentin remained, and the interglobular dentin, which originated from the incompletely 
calcified dentinal matrices between the calcified globules, were found in both the Dmp1-
/- and Dmp1-/-; Col1α1-NLSDMP1 mice (Fig. 3-2, c). In addition, larger collagen fibers 
(Fig. 3-3, d) and high levels of biglycan (Fig. 3-5, c) were present in the dentin or pre-
dentin in both the Dmp1-/- and Dmp1-/-; Col1α1-NLSDMP1 mice, compared to the control 
mice. Furthermore, DSPP, which is predominantly expressed in the odontoblast and is 
essential to dentin mineralization (78,79), was considerably decreased in both the Dmp1-
/- and Dmp1-/-; Col1α1-NLSDMP1 mice (Fig. 3-3, e). Scanning electron microscopy 
analysis showed that fewer dentinal tubules and branches in both Dmp1-/- and Dmp1-/-; 
Col1α1-NLSDMP1 mice (Fig. 3-3, f). Consistently, study of another independent mouse 
line (Line #97) (Fig. 3-7, d) showed the same result that NLSDMP1 did not improve the 
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Dmp1-/- dental defects. All of these data demonstrated that the NLSDMP1 transgene failed 
to rescue the defects during odontoblast differentiation and dentinal mineralization in 
Dmp1-/- mice. 
 
NLSDMP1 did not cure the defects of periodontal structures in Dmp1-/- mice 
We previously reported that Dmp1-/- mice developed an early-onset periodontal 
defect (17,34,72) and analyzed whether NLSDMP1 rescued the periodontal defects in 
Dmp1-/- mice. These mice displayed typical combined periodontal-endodontic lesions or 
tooth exfoliation at 1 year of age (Fig. 3-4, a), which was predominantly due to the loss 
of the periodontal attachment (Figs. 3-4, b-c).  Sirius Red staining further confirmed that 
the collagen content had decreased in the PDL (Fig. 3-5, arrows) and that the collagen 
fibers appeared to be thinner in polarized light image, suggesting the presence of more 
reticular fibers (Fig. 3-5, b) in both the Dmp1-/- and Dmp1-/-; Col1α1-NLSDMP1 mice, 
compared to the control mice. Biglycan staining also showed reduced biglycan protein in 
the PDL of the Dmp1-/- and Dmp1-/-; Col1α1-NLSDMP1 mice (Fig. 3-5, c). Furthermore, 
the alveolar bone was hypomineralized and not well organized in the Dmp1-/- and Dmp1-
/-; Col1α1-NLSDMP1 mice (Figs. 3-5, d-e). Collectively, these observations indicated that 
NLSDMP1 did not rescue the periodontal defects of the Dmp1-/- mice. 
 
NLSDMP1 did not prevent the delay of tooth eruption in Dmp1-/- mice 
Unexpectedly, we also discovered a delayed tooth eruption in the Dmp1-/- mice. 
At the age of 10 days, the first molars had not fully erupted and were still partially 
embedded in the bony crypts in both the Dmp1-/- and the Dmp1-/-; Col1α1-NLSDMP1 
mice (Figs. 3-6, a-b). The development of the bony crypt for the third molars was also 
delayed in the Dmp1-/- and Dmp1-/-; Col1α1-NLSDMP1 mice (Figs. 3-6, a-b). By the age 
of 3 weeks, these third molars had still not fully erupted compared to the control mice 
(Fig. 3-6, c). Furthermore, TRAP staining showed that there was a significant decrease 
in osteoclast number in both Dmp1-/- and Dmp1-/-; Col1α1-NLSDMP1 mice (Fig. 3-6, d; 
Fig. 3-7, c). These findings suggested that the delayed tooth eruption in the Dmp1-/- mice 
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might be due to a decrease in osteoclast formation and that NLSDMP1 did not rescue this 
defect. 
 
Discussion 
DMP1 is actively expressed in the mandibular odontoblasts, osteoblasts and 
osteocytes. In vitro studies suggested that the DMP1 C-terminal contains NLS signals 
and can function as a transcription factor during osteogenesis/odontogenesis (37). In this 
study, we investigated the potential nuclear function of the full-length DMP1 in vivo in 
odontogenesis using a clinical case and mutant mouse models. Our results showed that 
(1) DMP1 mutations (M1V, resulting in a loss of the ER-entry signal peptide but with 
the intact DMP1 preserved in the cell) led to enlarged pulp/root canals and thin dentin; 
(2) the nucleus-targeted DMP1 failed to rescue the tooth and periodontal structure 
defects in Dmp1-null mice; and (3) Dmp1-null mice unexpectedly developed delayed 
tooth eruption, which was not rescued by the nucleus-targeted DMP1 either. Thus, the 
current studies do not support the hypothesis that the full-length DMP1 has any nuclear 
function in vivo. 
We previously reported that the reexpression of secretory full-length DMP1 
under the control of a 3.6 kb Col1α1 promoter completely rescued the skeletal defects 
and serum biochemical abnormalities of Dmp1-/- mice by the age of 7 weeks (25). 
However, when the same 3.6 kb Col1α1 promoter was used to drive the expression of 
nucleus-targeted NLSDMP1, the construct failed to rescue the defects of the tooth and 
periodontal structures or the delayed tooth eruption observed in Dmp1-/- mice. In 
addition, we showed that the ARHR patient with a M1V mutation, which presumably 
affected the secretion of DMP1 but not its nuclear localization, manifested a typical 
rachitic tooth defect. These mouse and human genetic studies suggest that DMP1 might 
not have an apparent role in the nucleus in vivo. 
George’s group proposed that DMP1 might shuttle between the nucleus and 
extracellular milieu (37,39), as they observed that DMP1 contains both the functional 
NLS and the functional nuclear export signal (NES) sequences (37). They speculated 
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that during osteoblast/odontoblast differentiation, the extracellular DMP1 was taken up 
by the cells via GRP-78-mediated endocytosis and subsequently transported into the 
nucleus to regulate the expression of the osteoblast-/odontoblast-specific genes (39). 
They also proposed that during osteoblast maturation, DMP1 was phosphorylated and 
exported into the extracellular matrix to regulate matrix mineralization (37). In the 
current study, we demonstrated that NLSDMP1 was localized in the nuclei of Dmp1-null 
odontoblasts and that the M1V mutant DMP1 with the NLS signal in the intact molecule 
should be able to enter the nuclei. Therefore, both NLSDMP1 and M1V mutant DMP1 
should be exported into the ECM. However, we showed that NLSDMP1 was neither 
found in the matrix nor did it rescue any dental defects of Dmp1-/- mice. Furthermore, 
the ARHR patient with a M1V mutation developed a typical rachitic dental defect that 
was similar to those of other ARHR patients (22,34). 
Interestingly, our recent findings suggest that there might be a nuclear isoform of 
DMP1 (referred to as “nuDMP1”) translated from an alternative downstream in-frame 
start codon (AUG210 or AUG227 for mouse Dmp1) of the same mRNA that encodes 
the secretory DMP1 (80,81). This nuDMP1 form lacks the ER-entry signal sequence and 
the 37-kDa NH2-terminal sequence, but maintains the NLS sequence in its COOH-
terminal. Our studies revealed that the nuDMP1 enters the nucleus and regulates cell 
differentiation in vitro (80,81). It is possible that the 37-kDa NH2-terminal sequence may 
present a steric hindrance that interferes with the function of nuDMP1, as the 57-kDa 
COOH-terminal fragment of Dmp1 transgene fully rescued the Dmp1-/- defects (25). 
However, the intact DMP1 form with the mutated cleavage sites (i.e., no 37-kDa NH2 is 
removed from the COOH-terminal fragment) failed to rescue the Dmp1-null phenotype 
(47,74). Currently, we plan to test this theory by crossing the nuDMP1 transgene into the 
Dmp1-/- background. 
In summary, we have demonstrated that the nucleus-targeted full-length DMP1 
failed to rescue the dental defects in Dmp1-/- mice, suggesting that full-length DMP1 
plays no apparent role in the nucleus in vivo during odontogenesis.  
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CHAPTER IV 
A KEY PATHOLOGICAL ROLE OF WNT/Β-CATENIN IN HYPOPHOSPHATEMIC 
RICKETS 
 
Synopsis  
Deletion or mutation of Dmp1 or Phex leads to a hypophosphatemic 
rachitic/osteomalacic disorder, in which increased FGF23 plays a key pathological role. 
However, we recently found that elevated β-catenin expression levels in Dmp1-null and 
Hyp mice (Phex-deficient mice) also have a role in the development of 
hypophosphatemic rickets/osteomalacia. To affirm this hypothesis, we first crossed 
Dmp1-null mice with 2.3 Col 1-Dkk1 transgenic mice, generating offspring that over-
expressed DKK1 (a potent inhibitor of the Wnt/β-catenin signaling pathway) in the 
osteoblasts and osteocytes. By 3 weeks, the targeted expression of DKK1 and 
consequent blockade of Wnt/β-catenin signaling significantly improved the following 
elements of the rachitic/osteomalacic phenotype: 1) FGF23, PTH, Pi and Ca levels; 2) 
skeleton length (long bone and vertebrae); 3) growth plate thickness; 4) epiphysis and 
metaphysis phenotype; 5) cell proliferation (BrdU); 6) molecular bone markers (OSX, 
BSP, OPN, Col I, Biglycan); and 7) bone mineralization and formation rates. By 8 
weeks, the Dmp1-null phenotype had further improved. Moreover, the DKK1 transgene 
also partially rescued the Hyp mice. Further analysis indicated this elevated Wnt/β-
catenin signaling activity was responsible for the maturation defects of the osteocytes, 
since the constitutive expression of β-catenin specifically in the osteocytes recaptured 
the osteomalacia phenotype. In addition, the anti-Wnt signaling compound treatment 
also improved the rachitic phenotype in the Dmp1-null mice. Taken together, we 
demonstrated that an abnormally high level of Wnt/β-catenin expression in Dmp1-null 
mice and Hyp mice was a key pathological local factor responsible for defects in the 
osteoblast/osteocyte maturation leading to hypophosphatemic rickets/osteomalacia.  
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Introduction 
Dentin matrix protein 1 (DMP1) is expressed predominantly in odontoblasts in 
tooth and osteocytes in bone (6,8,9,48). The deletion of murine Dmp1 causes striking 
defects in tooth and bone during postnatal development in mice that are similar to the 
DMP1 mutations in autosomal recessive hypophosphatemic rickets (ARHR) patients (3). 
ARHR, together with x-linked dominant hypophosphatemic rickets (XLH, caused by 
PHEX gene mutation) (1) and autosomal dominant hypophosphatemic rickets (ADHR, 
resulting from FGF23 gene mutation) (2), were considered to be heritable 
hypophosphatemic rickets/osteomalacia. These inherited diseases make up a group of 
disorders characterized by hypophosphatemia, which results from inherited gene 
mutation and leads to dietary phosphorus deficiency and/or disorders of renal phosphate 
wasting. The characteristics of inherited hypophosphatemic rachitic/osteomalacic 
disorder included short stature, skeletal deformities, cartilaginous defects, tooth 
abnormalities and changes of serum biochemistry markers. Furthermore, our recent 
studies suggested that DMP1 likely regulates the downsizing process in osteoblastic 
protein expression and metabolic activity during the maturation of osteoblasts into 
osteocytes (16). It is indicated that DMP1 regulates normal osteoblast-to-osteocyte 
maturation and its deletion would disrupt the differentiation process (16). However, 
other molecular and cellular mechanisms involved in DMP1 regulation are largely 
unknown.   
It is well known that fibroblast growth factor 23 (FGF23) is a key factor in the 
pathogenesis of hypophosphatemic rickets/osteomalacia (3,82-85). Studies have shown 
that FGF23, as a potent phosphaturic hormone, is significantly up-regulated in the 
osteocytes and then targets the kidneys to promote renal excretion of phosphate, which 
led to decreased serum phosphorus levels in Dmp1-null mice and Hyp mice (3,16,84-87). 
However, the restoration of phosphate homeostasis by a higher phosphate diet or FGF23 
antibody injection only partially rescues the bone formation rate and osteomalacia, as 
well as the maturational defects of osteocytes (16). As a result, it was suggested there 
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could be other factors or signal pathways involved in the development of the 
rickets/osteomalacia phenotype in these mice.  
Some of our previous results implied that canonical Wnt/β-catenin signaling may 
be involved in the phenotype formation primarily because the serum biochemistry 
analyses of Dmp1-null mice showed that the parathyroid hormone (PTH) levels 
increased more than 5-fold. PTH was able to induce β-catenin stabilization through the 
low-density lipoprotein receptor-related protein (LRP) 6 and PTH receptor (88,89). 
Secondly, a dramatically decreased expression of sclerotin (SOST), an inhibitor of the 
Wnt/β-catenin pathway, was found in the osteocytes of Dmp1-null mice (16). As a target 
downstream of SOST, canonical Wnt/β-catenin signaling could be abnormally up-
regulated in the Dmp1-null osteocytes. As a result, we hypothesized that there was an 
increased expression of β-catenin in the Dmp1-null osteocytes and that this ectopic 
activity of β-catenin might cause the disruption of the maturational progress of the late 
osteo-lineage (including osteoblast differentiation and osteocyte maturation), 
subsequently leading to defective bone mineralization and porosity. 
In this study, we identified that an up-regulation of Wnt/β-catenin signaling 
activity in Dmp1-null was one of key factors affecting the osteoblast differentiation and 
osteocyte maturation. We then normalized the β-catenin level in both Dmp1-null mice 
and Hyp mice by crossing them with DKK1 transgenic mice (2.3 Col 1α1-DKK1). We 
evaluated the bone morphology and mineralization, osteocyte and osteoblast maturation 
and function, and biochemical testing; all the tests indicated a significant rescue of the 
osteomalacia phenotype in these mice. In addition, we also cured the osteomalacia 
defects of Dmp1-null mice using an anti-β-catenin compound injection. Altogether, these 
results suggested that the increased activity of the canonical Wnt signaling pathway was 
a key factor, except for FGF23, which was responsible for the development of 
hypophosphatemic rickets/osteomalacia by regulating the maturational process and 
biological functions of osteocytes.  
 
 
 42 
 
Subjects and Methods 
Constitutive stabilization of β-catenin in osteocytes in vivo 
Two kinds of mice were used to investigate the role of increased β-catenin 
activity in osteocytes in vivo. Mice with the targeted β-catenin gene (exon 3) located 
within loxP sites (β-catex3loxP/loxP) (90) were obtained from the Jackson Laboratory (Bar 
Harbor, ME, USA) and were crossed with Dmp1-Cre transgenic mice, which express 
Cre recombinase selectively in osteocytes under the control of a 14 kb promoter 
fragment of the Dmp1 (91). Heterozygous mice with constitutively activated β-catenin 
specifically in the osteocytes (Dmp1-Cre; β-catex3loxP/+, referred to as “CA-β”) were 
generated from crossing both mouse lines, and the progeny were analyzed. The data 
obtained from Dmp1-Cre transgenic mice were pooled and used as controls (referred to 
as “Cont”). All of the mice were fed with autoclaved Purina rodent chow (Ralston 
Purina, St. Louis, MO, USA) containing 1% calcium, 0.67% phosphorus, and 4.4 IU of 
vitamin D/g. All animal procedures were performed in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by 
the Institutional Animal Care and Use Committee of Texas A&M University Baylor 
College of Dentistry (Dallas, TX, USA). 
 
Dkk1 transgene in Dmp1-null or Hyp-mice  
The Dkk1 transgene (46) was driven by the 2.3 kb Col 1α1 promoter in the 
transgenic Dkk1 mice. These mice were crossed with Dmp1-null mice (8) and Hyp-mice 
(92). Among their offspring, WT mice were used as the control group. Other groups of 
mice included Dkk1-Tg with wild type background (DKK1), Dkk1-Tg with Dmp1 
knockout background (DKK1; KO), Dkk1-Tg with Phex inactivated mutation (DKK1; 
Hyp), Dmp1 conventional knockout (KO); and loss-of-function mutation of Phex (Hyp). 
The genetic backgrounds of all the mice were uniform mixtures of CD1-C57BL/6J.  
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Anti-β-catenin compound injection 
A compound drug that acts as an inhibitor of Wnt response (IWR-1) was kindly 
provided by Dr. Lawrence Lum (University of Texas Southwestern Medical Center, 
Dallas, TX) as a gift (93).  Briefly, IWR-1 is a small molecule (M.W. 410.2) that inhibits 
Axin2 protein destruction. To make the injection formulation, IWR-1 was dissolved in 
N,N-dimethylacetamide, Cremophor EL, and sodium bicarbonate (ph=9.0) (Sigma-
Aldrich, St. Louis, MO, USA). One-week-old mice were injected (i.p.) daily (7.1mg/kg) 
(referred to as “KO+IWR”) and sacrificed at four weeks. Their littermates injected with 
the vehicle were used as the controls (referred to as “HET+Vehicle” or “KO+Vehicle”). 
 
PCR genotyping 
Genomic DNA was extracted from a tail biopsy done on each mouse and used 
for genotyping by PCR analysis. The primers used were the following: LacZ (forward: 
5’-GAG TGC GAT CTT CCT GAG GCC GAT ACT GTC-3’ and reverse: 5’-CGC 
GGC TGA AAT CAT CAT TAA AGC GAG TGG-3’; 490 bp); endogenous Dmp1 
(forward: 5’-GCC CCT GGA CAC TGA CCA TAG C-3’ and reverse: 5’-CTG TTC 
CTC ACT CTC ACT GTC C-3’; 337 bp); Dkk1-Tg (forward: 5’-ATT CCA ACG CGA 
TCA AGA ACC TG-3’ and reverse: 5’-GCA AGC CAG ACA GAT CTG TAC-3’; 236 
bp); Phex (forward: 5’-CCA AAA TTG TTC TTC AGT ACA CC-3’ and reverse: 5’-
ATC TGG CAG CAC ACT GGT ATG-3’; 258 bp); Cre (forward: 5’-CCC GCA GAA 
CCT GAA GAT G-3’ and reverse: 5’-GAC CCG GCA AAA CAG GTA G-3’; 534 bp); 
β-catex3loxP (forward: 5’-AGG GTA CCT GAA GCT CAG CG-3’ and reverse: 5’-CAG 
TGG CTG ACA GCA GCT TT-3’; 646 bp). The reagents and conditions used were as 
previously described (25). 
 
Histomorphometric and immunohistological analyses   
The animals were injected with BrdU (5-Bromo-2’-deoxyuridine, 100 ug/g 
mouse, i.p.; Sigma-Aldrich, St. Louis, MO, USA) once a day and injected twice before 
they were sacrificed. Perfusion of the mouse heart chamber with freshly prepared 4% 
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paraformaldehyde in PBS (pH 7.4) was used for sacrifice. The samples were further 
fixed in the same fixation solution for 2 days in 4°C and then stored in 0.5% 
paraformaldehyde/PBS. The long bones were dissected from the whole body, free of 
muscle, and then decalcified and embedded in paraffin as described previously (8). 
Sections were cut (4.5 µm) and mounted on slides and dried. After dewaxing and 
rehydration, they were used for histomorphometric and immunohistological analyses. 
The methods included Hematoxylin & Eosin (HE), Sirius Red, TRAP, BrdU (BrdU 
staining kit, Invitrogen, Grand Island, NY, USA), in situ hybridization, and 
immunohistochemistry staining, as formerly reported (3). The antibodies and probes 
used were the following: anti-Biglycan monoclonal antibody (24), anti-osterix (OSX) 
monoclonal antibody (Abcam, Cambridge, MA, USA), anti-osteopontin (OPN) 
monoclonal antibody (Santa Cruz Biotechnology, TX, USA) and anti-bone sialoprotein 
(BSP) monoclonal antibody (51,94) anti-E11 polyclonal antibody (64), anti-DMP1-C-
terminal polyclonal antibody (59), anti-sclerostin polyclonal antibody (R&D 
Biosystems, Minneapolis, MN, USA), anti-dickkopf-1 (DKK1) polyclonal antibody 
(R&D Biosystems, Minneapolis, MN, USA), and anti-β-catenin monoclonal antibody 
(Sigma-Aldrich, St. Louis, MO, USA).  
 
Mineral deposition analysis  
To evaluate the amount of mineralization, the mice were injected (i.p.) with 
calcein green (5 mg/kg, Sigma-Aldrich, St. Louis, MO, USA), followed by injection of 
an Alizarin Red (5 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) 5 days later. The mice 
were sacrificed 48 hours after the second label, and the bones were dissected free of 
muscle and then fixed in 70% ethanol for 3 days. Later, the undecalcified bones were 
dehydrated in ascending concentrations of ethanol (from 70% to 100%) and embedded 
in methyl methyacrylate (MMA, Buehler, Lake Bluff, IL) and sectioned (6 mm) using a 
Leica 2165 rotary microtome (Ernst Leitz Wetzlar). These sections were photographed 
using a Leica SP5 confocal microscope for fluorochrome labeling. The mineralization of 
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the same samples was analyzed with Goldner Masson’s trichrome staining and 
photographed with a wide field light microscope, as described previously (3). 
 
In vivo β-galactosidase analysis  
Mice with the top-gal (95), a β-galactosidase gene under the control of the 
lymphoid enhancing factor (LEF)/T cell factor (TCF) (DNA-binding protein complex 
that acts in concert with nuclear localized β-catenin) and c-fos (β-catenin inducible 
promoter) were crossed with Dmp1 conditional knockout mice (3.6 kb Col I-Cre; 
Dmp1loxP/loxP). In the offspring with a top-gal transgene, the β-galactosidase expression 
was directly stimulated by a stabilized form of β-catenin, but was also dependent upon 
LEF/TCF in the bone. Top-gal transgenic mice without the conditional Dmp1 knockout 
background were used as controls (referred to as “Top-gal+”), whereas mice with Top-
gal+; 3.6 kb Col I-Cre; Dmp1loxP/loxP (referred to as “Top-gal; CKO”) were used as the 
experimental group. β-galactosidase staining was performed as previously described 
(91). 
 
High-resolution radiography, microcomputed tomography (µ-CT) and scanning 
electron microscopy (SEM) 
Long bone radiographs were taken using a Faxitron model MX-20 Specimen 
Radiography System with a digital camera (Faxitron X-Ray Corp., Lincolnshire, IL, 
USA). The µ-CT analysis was performed using a Scanco µCT35 (µCT35; Scanco 
Medical, Bassersdorf, Switzerland). The cortical porosity was obtained from analyzing 
the midshaft of each group. One hundred cross-sectional slices of the midshaft were 
analyzed at the threshold of 283. Scanning electron microscopic (SEM) images were 
taken using the MMA-embedded long bone as previously described (3). The samples 
were cut to expose the cortical surface and then polished using 1 µm and 0.3 µm alumina 
alpha micropolish II solution (Buehler). This step was followed by acid etching with 
37% phosphoric acid for 2 to 10 seconds, 5% sodium hydrochloride for 5 minutes and 
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then coated with gold and palladium. The scanning electron microscopy was performed 
with a FEI/Philips XL30 field-emission environmental SEM (Hillsboro, OR, USA). 
 
Quantitative real-time PCR   
Total RNA was extracted from mouse long bones using the Trizol reagent 
(Invitrogen, San Diego, CA, USA) and then reverse-transcribed into cDNA using the 
Super Script first-strand synthesis system (Invitrogen, San Diego, CA, USA). The real-
time PCR analysis of β-catenin and Fgf23 was done using TaqMan Gene Expression 
Specific Probes (Life Technologies, NY, USA), and GAPDH (used as an internal 
control, forward primer, 5’-ACC ACA GTC CAT GCC ATC AC-3’, and reverse primer, 
5’-TCC ACC ACC CTG TTG CTG TA-3’). The SYBR Green System (Applied 
Biosystems, Carlsbad, CA, USA) was used as described in our previous studies (25).   
 
Protein extracts and western blot 
The total protein was extracted from both wild type (WT) and Hyp mouse long 
bones under the same conditions. The concentrations were adjusted according to the 
instructions for the BCA kit (Pierce, Rockford, IL, USA). Ten µg of total protein from 
each group at a concentration level of 0.2 µg IgG/ml was subjected to 10% SDS-PAGE 
gel, followed by blotting onto a polyvinylidene difluoride membrane. Anti-β-catenin-
antibodies (Cell Signaling, Danvers, MA, USA) were used (1:1000) for detection. An 
anti-β-actin-antibody (Cell Signaling, Danvers, MA, USA) was used as an internal 
control. The blots were washed and incubated with a color development reagent 
(Ambion, Grand Island, NY, USA). The bands were assayed with a Kodak film imaging 
system (Perkin Elmer, Waltham, MA, USA) after 5 min exposure. 
 
Serum biochemistry 
Mouse blood was collected through heart punctures, and serum was obtained by 
precipitation and centrifugation at 6,000 rpm for 30 min. The serum FGF23, phosphorus 
(Pi), Calcium (Ca) and PTH levels were determined as previously described (3). 
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Statistical analysis 
The data from the two experimental groups were analyzed by student’s T test, 
while the data sets with more than two groups were analyzed using a one-way ANOVA. 
If significant differences were found, the Bonferroni method was used to determine 
which groups were significantly different from the others. The quantified results were 
represented in mean ± standard error of the mean (SE). We considered P<.05 as 
statistically significant. 
 
Results 
Elevated Wnt/β-catenin signaling pathway activity in Dmp1-null mice 
We reported previously that the serum PTH level (3) and the expression level of 
SOST were notably down-regulated (16) in the Dmp1-null mice. As the anti-SOST 
immunostain (Fig. 4-1, left) indicated, SOST is normally produced primarily by 
osteocytes and is abundant in the osteocytic canalicular system and bone surface. There 
it interacts with late-osteoblast/preosteocyte and lining cells so as to regulate their status 
(quiescent or mature) via the canonical Wnt/β-catenin signaling pathway (96-98). SOST 
remarkably decreased in the osteocytes of the Dmp1-null mice (Fig. 4-1, left), which 
may have led to abnormal Wnt/β-catenin signaling activity. To further clarify this 
hypothesis, we first analyzed both the mRNA and protein expression levels of β-catenin 
in the long bones, and the results suggested a significant increase of β-catenin in the 
Dmp1-null mice (Figs. 4-2, a-b), especially in the osteocytes, compared to the controls. 
We then further tested whether this increased β-catenin level was transported into the 
nucleus and regulated gene expression. TCF, one of the direct downstream genes of β-
catenin that serves as a transcriptional co-activator regulating gene expression, was 
detected using Top-gal staining of the Dmp1 conditional knockout mice (Fig. 4-2, c) and 
in situ hybridization of the Dmp1-null mice (Fig. 4-2,d). The results supported the 
immnunohistochemical analysis that the Wnt/β-catenin signaling in the Dmp1-null 
osteocytes was elevated, compared to the controls. Taken together, Dmp1 deletion led to 
the increased activity of Wnt/β-catenin signaling, which targeted the osteocytes and may 
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have been responsible for the development of the rickets/osteomalacia phenotype in the 
Dmp1-null mice. 
 
β-catenin regulated osteocyte maturation and function 
To demonstrate the hypothesis that the up-regulated Wnt/β-catenin activity in 
osteocytes was responsible for its maturational defect, we specifically induced β-catenin 
expression in the osteocytes by crossing the Dmp1-Cre mice with β-catex3loxP/loxP mice, 
which introduced a constitutive stabilization of β-catenin in the osteocytes. The offspring 
had a rickets-/osteomalacia-like phenotype, including short stature (Fig. 4-3, a), cortical 
bone porosity (Fig. 4-3, b), and hypomineralization (Figs. 4-4, a-c). The histological 
images suggested that, compared with the controls, the matrix of the mutant cortical 
bone was filled with type I collagen (Col I) and biglycan, which is a small leucine-rich 
repeat proteoglycan that interacted with Col I (99,100) and appeared to have an 
increased osteoid area. These results highly indicated that the mineralization of the 
cortical bone in the mutant mice was suppressed compared to the controls. 
Immunohistochemistry labeling of the osteogenic markers [OSX (Fig. 4-4, d) and OPN 
(Fig. 4-4, e) for the osteoblasts, E11 (Fig. 4-4, f) for newly formed osteocytes] 
demonstrated that the ectopic β-catenin levels in osteocytes led to the maturational 
defect (Figs. 4-4, d-f). Cell proliferation analysis (Fig. 4-3, c; Fig. 4-4, g) indicated that 
the osteocytes in the CA-β mice maintained their proliferation abilities, which further 
supported the idea that there was an interrupted maturational process. However, serum 
biochemistry testing showed the Pi, FGF23 and Ca levels hadn’t significantly changed 
(Table. 4-1), but PTH had significantly up-regulated. Collectively, these data 
consistently supported the idea that the evaluated activity of Wnt/β-catenin signaling in 
osteocytes cause their maturational and functional defects, leading to an osteomalacia 
phenotype. 
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Normalized Wnt/β-catenin activity significantly rescued the rickets/osteomalacia in 
Dmp1-null mice 
To further investigate whether the abnormal activity of canonical Wnt signaling 
could be one of the pathological reasons for the development of hypophosphatemic 
rickets/osteomalacia in Dmp1-null mice, Dkk1 transgenic mice were introduced into the 
Dmp1-null background to down-regulate the β-catenin expression. DKK1, like SOST, 
inhibits the Wnt/β-catenin signaling pathway. DKK1 bound to the kremen and LRP5/6 
interrupted the interaction between Wnts and the LRP5/6 co-receptor (101). Using the 
2.3 kb Col1α1 promoter specific to osteoblasts and osteocytes, our studies also showed 
that the transgenic over-expression of Dkk1 in WT mice did not cause notable early long 
bone deficiencies (Figs. 4-5). As a result, we crossed the Dkk1-Tg mice with Dmp1-null 
mice for over-expression of Dkk1 in the Dmp1-null background. The representative 
radiographs and µ-CT analysis demonstrated an apparent improvement of the epiphysis 
and metaphysic structures, long bone shape, and cortical porosity in the DKK1; KO 
group, compared to the Dmp1-null group (Fig. 4-5). 
The expressions of DMP1, DKK1 and β-catenin in the offspring were evaluated. 
As predicted, DMP1 was not detectable in the Dmp1-null mice (KO, Fig. 4-6, a), and 
DKK1 was highly expressed in the transgenic osteoblasts and osteocytes, compared to a 
weak expression in the WT osteocytes and an almost undetectable expression in the KO 
osteocytes (Fig. 4-6, b). As we anticipated, β-catenin was markedly normalized in the 
DKK1; KO group (Fig. 4-6, c). A series of experiments was performed to assess whether 
the targeted expression of the DKK1 in the Dmp1-null mice showed the rescue effects. A 
close examination of the metaphysis area revealed that the abnormal bone homeostasis, 
including increased bone formation (OSX, BSP, OPN, Figs. 4-7, a-d) and decreased 
bone absorption (TRAP, Figs. 4-7, e), also significantly rescued the Dmp1-null 
phenotype by re-regulating the Wnt/β-catenin activity with Dkk1-Tg. Further analysis 
suggested the ectopic Wnt/β-catenin activity could lead to both significantly up-
regulated osteoblast proliferation activity (BrdU, Figs. 4-7, f), and significantly down-
regulated osteoclast number in the primary spongiosa (TRAP, Figs. 4-7, g), since the 
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Dkk1-transgene significantly rescued these abnormal bone cell activities. Analysis of the 
mineral deposit (double labeling, Fig. 4-8, a) and bone mineralization (Goldner, sirius 
red, and biglycan staining, Figs. 4-8, b-d) indicated a prominent rescue of the 
osteomalacia phenotype in the DKK1; KO mice, suggesting that Wnt/β-catenin signaling 
is important for the pathological development of the osteomalacia phenotype in Dmp1-
null mice. Further analysis of osteocytes, including analysis of bone markers (OSX, E11, 
SOST), osteocyte morphology, mineralization of the pericellular matrix, and cell 
proliferation, confirmed that lowering the β-catenin level in Dmp1-null mice resulted in 
well formed osteocytes with almost normal functions. In another words, it remarkably 
rescued the maturation defect of the Dmp1-null osteocyte (Fig. 4-9). This result 
suggested the osteocyte maturation and mineralization defects in Dmp1-null mice could 
directly or indirectly cause the elevated osteocytic Wnt/β-catenin signaling activity. 
However, DKK1 only partially rescued the serum biochemistry markers (including Pi 
and FGF23) in Dmp1-null mice (Table. 4-1), in accordance with the previous studies 
showing that the hypophosphatemia phenotype in Dmp1-null mice is primarily regulated 
by the abnormal production of FGF23 (3,102). Taken together, the genetic rescue of 
Dmp1-null via the Dkk1 transgene indicated that except for up-regulated FGF23, which 
is responsible for the pathogenesis of hypophosphatemia in Dmp1-null mice, the 
osteocytic canonical Wnt signaling pathway also plays an important pathological role 
during hypophosphatemic rickets/osteomalacia development, especially the osteomalacia 
phenotype, via regulating the osteocyte maturation. 
 
Down-regulation of Wnt/β-catenin activity rescued the defects of Hyp mice 
XLH, another common type of hypophosphatemic rickets/osteomalacia with an 
incidence of 1:20,000 live births, resulted from Phex gene mutation (24). Cloning the 
Phex gene mutation in murine homologs generated a typical hypophosphatemic animal 
model named “Hyp” mice (1,103). Recently, Yuan et al. (104) identified a decrease in 
the 7B2 chaperone protein (“Signe” gene) in Hyp mouse osteocytes/osteoblasts that 
consequently diminished the 7B2PC2 enzyme activity. The 7B2PC2 enzyme was 
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demonstrated to be an important regulator of the DMP1 process due to its effects on 
BMP1, the only identified enzyme for DMP1 processing (105). Full-length DMP1 works 
as a precursor that was cleaved into functional forms – the 57 kDa C-terminal and 37 
kDa N-terminal (15). As a result, DMP1 lost its biological function in Hyp mice. Thus, 
serum biochemistry analysis confirmed that, similar to the Dmp1-null mice, FGF 23 
significantly increased in the Hyp mice (Fig. 4-10, a), which resulted in the abnormal 
production of FGF23 in bone cells (Fig. 4-10, b, >3 fold) and played an essential 
pathogenic role in Hyp mice (85,86). More importantly, β-catenin also increased (over 9 
-fold) in the Hyp mice (Figs. 4-10, c-d), consistent with the Dmp1-null mice. As a result, 
we also crossed Dkk1-Tg mice with Hyp mice to further identify whether Wnt/β-catenin 
was responsible for hypophosphatemic development in the absence of functional DMP1. 
The results of serum biochemistry analysis suggested the hypophosphatemia phenotype 
wasn’t effectively rescued when the canonical Wnt pathway was blocked, based on the 
results from the DMP1 groups (Table 4-1). However, bone morphology and histology 
analyses revealed an apparent improvement of the skeletal abnormalities in the DKK1; 
Hyp mice (Figs. 4-10, e-f). These data were consistent with the rescue results obtained 
from DKK1; Dmp1-KO mice, suggesting the osteomalacia abnormality in the Hyp mice 
was also caused by the increased Wnt/β-catenin activity. 
 
Injection of anti-β-catenin compound drug improved the rickets/osteomalacia 
deficiency in Dmp1-null mice  
Normalization of the Wnt/β-catenin expression in both the Dmp1-null mice and 
Hyp mice consistently showed a significant improvement of the ostomalacia phenotype 
but only partially restored the hypophosphatemia. The normalized expression further 
confirmed that Wnt/β-catenin worked as a local factor regulating the osteocyte 
maturation and function. To address the clinical translation of this discovery, a 
compound drug named “IWR,” that inhibits Wnt/β-catenin signaling was used to treat 
the Dmp1-null mice. The IWR compound was designed to inhibit the Wnt-induced 
accumulation of β-catenin by abrogating Axin protein turnover (93,106-108). Axin 
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protein was part of the β-catenin destruction complex, which consists of adenomatous 
polyposis coli (Apc), Axin, casein kinase (Ck) 1 and glycogen synthase kinase (Gsk) 3β 
that promoted proteasome-mediated proteolysis of phosphorylated β-catenin (108,109). 
Daily IWR injections started at 1 week of age and continued for 3 weeks. The injection 
group, together with both WT and Dmp1-KO mice with vehicle injections (as controls), 
were collected at 4 week of age. Bone morphological and histological analysis revealed 
that anti-β-catenin compound (IWR) rescued the rickets/osteomalacia phenotype in 
Dmp1-null mice (Fig. 4-11, a-c). This result suggested a new clinical drug strategy for 
the treatment of heritable hypophosphatemic rickets/osteomalacia patients. Since the 
current oral supplementation of phosphorus couldn’t fully cure the symptoms of these 
patients, especially the bone hypomineralization, the combination of an anti-β-catenin 
drug and dietary intake of phosphate should be developed for a better therapeutic effect. 
 
Discussion 
   Previous studies from several groups confirmed that FGF23 influenced the serum 
phosphorus level, which was critical for bone and tooth malformation in mice with 
hypophosphatemic rickets/osteomalacia (3,16,84-86,110). In this study, we first 
identified the up-regulation of Wnt/β-catenin signaling activity in osteocytes. Further 
analysis of both ectopic activation and reasonable down-regulation of osteocytic β-
catenin confirmed that Wnt/β-catenin was one of the key factors regulating osteocyte 
maturation and its function. Taken together, our results strongly suggested that in 
addition to the FGF23, the Wnt/β-catenin signaling pathway also played an important 
role during the pathogenesis of hypophosphatemic rickets/osteomalacia, especially the 
osteomalacia development via regulation of osteocyte maturation and function (Fig. 4-
12).  
In the canonical Wnt signaling pathway, when certain Wnts or other triggers 
were present, they crosslinked cell surface molecules, Lrp5/6 and Frizzled (Fzd), which 
mobilized Gsk3β and Ck1 to the membrane where they phosphorylated serines on 
Lrp5/6, promoted the formation of a signalosome, and recruited disheveled (Dvl) and 
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axin1/2. This released β-catenin, increased its levels and entered the nucleus to regulate 
bone-related genes, such as Tcf/Lef1 and axin2 (109,111-113). It was well documented 
that the Wnt/β-catenin pathway is necessary for osteogenesis and bone remodeling via 
regulation of early osteo-lineage (113-115). However, the function of canonical Wnt 
pathway on the terminally differentiated osteocytes making up almost 90% of the total 
bone cells was largely unknown. Previous evidence suggested there was a close 
relationship between the Wnt/β-catenin signaling pathway and osteocytes either directly 
or indirectly. For example, Bonewald et al. found that Wnt/β-catenin signaling was 
activated upon mechanical loading in osteocytes (116). Two major Wnt inhibiters 
important for regulating osteogenesis (SOST, DKK1) were postnatally produced by 
osteocytes (Fig. 4-1; Fig. 4-5, b) (16,117-119). In addition, a recent study showed 
osteocyte Wnt/β-catenin signaling was required for normal bone homeostasis via 
regulation of osteoclast activity (120,121), while in this study, we further investigated 
the role of Wnt/β-catenin signaling in regulating osteocytes. Our results strongly 
suggested that Wnt/β-catenin signaling regulated osteocyte maturation and function by 
controlling the osteoblast-osteocyte transition and that keeping a low level of β-catenin 
in osteocytes was essential for bone modeling and remodeling (Fig. 4-12).  
We have shown that the ectopic expression of Wnt/β-catenin was negative for 
osteocyte maturation and function; however, it did not mean less was better. Actually, 
osteocytic Wnt/β-catenin signaling should be maintained at a specific level. Studies from 
Kramer et al. indicated that osteocyte-specific β-catenin-deficient mice (Dmp1-Cre; β-
catloxP/loxP) displayed progressive bone loss associated with increased osteoclast number 
and activity, which was due to a reduction in the osteocytic OPG and increased 
osteocytic RANKL/OPG ratio (121). Collectively, Wnt/β-catenin signaling was more 
like a “valve” that could be turned on during the early osteo-lineage formation (from 
mesenchymal stem cell to osteoblast progenitor) as a key regulator of osteoblastogenesis 
and expression in early osteo-lineage, which was necessary for osteogenic differentiation 
and maturation (122-126). However, this “valve” would be progressively turned down to 
a specific level during the differentiation and maturation of osteoblast/osteocytes. This 
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down-regulation might be controlled by a simultaneously increased expression of several 
Wnt antagonists including secreted frizzled-related protein 1 (Sfrp1), DKK2 and SOST 
(117,119,127-130). The adjustment of Wnt/β-catenin signaling would consequently 
promote osteocyte maturation and was important for normal bone homestasis. 
Increased serum PTH levels were found in both Dmp1-null and Hyp mice 
(3,131). Previously it was thought the up-regulation of serum PTH resulted from the 
high serum FGF23 level. Briefly, the FGF23-mediated down-regulation of 1,25(OH)2D3 
synthesis reduced intestinal Ca absorption and thus also the serum Ca, which stimulated 
PTH release. However, serum Ca levels in the Dmp1-null mice didn’t significantly 
change (3). Interestingly, a recent study suggested that murine FGF23 directly inhibited 
PTH synthesis in a mitogen-activated protein kinase (MARK)-dependent manner 
(132,133). Therefore, other mechanisms might be responsible for the up-regulation of 
PTH. In this study, we found that none of serum biochemistry markers were 
considerably changed in the CA-β group except for the PTH level, suggesting the up-
regulated Wnt/β-catenin signaling in osteocytes was one of the possible causes for 
elevated serum PTH. A study by Guo et al. demonstrated that a certain amount of Wnt 
signaling was required to enable PTH to induce peritrabecular stromal cells and 
subsequent bone formation (134). Furthermore, several studies confirmed that PTH 
activated canonical Wnt signaling through the co-receptor Lrp6 (88,89,134). 
Collectively, based on the current studies, we think the increased Wnt/β-catenin in the 
osteocytes of the hypophosphatemic mice led to a higher serum PTH level through an 
unknown mechanism, and this increased serum PTH further activated the canonical Wnt 
signaling in bone cells, forming a positive feedback loop. 
For several decades, the disorder of the functional axis of the FGF23-renal 
phosphorus reabsorption-serum phosphorus level was well established as a major factor 
in the pathogenesis of inherited hypophosphatemic rickets/osteomalacia. However, the 
restoration of phosphate homeostasis only partially rescued the rickets/osteomalacia 
phenotype, suggesting that other factors or signaling pathways could work as a local 
pathological mechanism. This study found that Wnt/β-catenin is one of the underlying 
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mechanisms, which enabled a more comprehensive understanding of the pathological 
development and biochemical regulation of hypophosphatemia. It also has clinical 
relevance, as an oral phosphorus therapy alone fails to fully restore the osteomalacic 
status in patients, and thus, genetic therapy that normalizes the Wnt/β-catenin signaling 
may benefit these patients. 
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CHAPTER V 
CONCLUSION 
 
DMP1 is essential for both odontogenesis and osteogenesis. Previous in vitro 
studies suggested that, in addition to its role as an ECM protein, DMP1 could also 
function as a transcription factor. However, this nuclear transcription theory was 
debatable. Moreover, the loss-function of DMP1 in vivo would lead not only to the 
hypophosphatemia but also to the osteomalacia defect. The hypophosphatemia 
phenotype was well demonstrated as a result of the increased expression of FGF23 in 
osteocytes; however, the underlying mechanism of the osteomalacia phenotype still 
needs to be identified. In this study, we investigated the potential nuclear function of the 
full-length DMP1 in osteogenesis and odontogenesis using both in vivo and in vitro 
methods. Our results showed that the nucleus-targeted DMP1 failed to rescue the bone 
and tooth defects in Dmp1-null mice, indicating that DMP1 worked mainly as an ECM 
protein that, as we and others previously reported, functions via the extracellular signal-
regulated kinases (ERK)-mitogen-activated protein kinases (MAPK) pathway. We also 
identified an up-regulation of the Wnt/β-catenin signaling activity in the osteocytes. 
Further analysis of both the ectopic activation and reasonable down-regulation of 
osteocytic β-catenin confirmed that Wnt/β-catenin was a key factor in regulating 
osteocyte maturation and function. Taken together, our results confirmed that DMP1 
regulated the osteocytes via both ERK-MAPK and the canonical Wnt signaling 
pathways.  
 
Important Roles of Osteocytes 
The osteocyte, defined as the terminally differentiated cells derived from 
osteoblasts located within the bone matrix, comprises more than 90% to 95% of all bone 
cells in the adult skeleton. Previously, osteocytogenesis was considered a passive 
process, during which osteoblasts produced a matrix/osteoid and became trapped under 
new osteoid over the embedded cells (135,136). However, in the last decade, there was a 
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virtual explosion of data on the molecular biology and function of osteocytes. Far from 
being the “passive placeholder in bone”, this cell type has demonstrated numerous 
functions, such as remodeling the bone (137), producing hormones such as the 
parathyroid hormone (138-140) and estrogen (141,142), acting as a mechanosensory cell 
(143), regulating bone resorption via osteoclasts (70,144), and working as an endocrine 
cell via connections with the vascular system (145). More clinic observations indicated 
osteocytes were important for bone mineralization and maintenance. For example, the 
functional disorder of osteocytes leads to osteoporosis, a disease affecting 55% of 
Americans aged 50 or above and is responsible for millions of fractures annually (146-
148). The differentiation of osteoblasts into osteocytes occurs in several stages, 
including osteoid osteocyte (or newly formed osteocyte), mineralized osteocyte, and 
mature osteocyte (26). However, the molecular and cellular mechanisms governing this 
maturation process and the functions of osteocytes have been largely unknown due to the 
lack of appropriate research techniques. Therefore, the osteocyte was one of the key cells 
involved in skeleton development and homeostasis, and the identification of the 
mechanisms underlying its differentiation and maturation process helped to further the 
understanding of bone biology in order to develop skeletal disease therapy.  
 
Signaling Involved in the Biological Regulation of DMP1 
DMP1, one of acidic phosphorylated extracellular matrix proteins specifically 
produced by osteocytes, was identified as a key regulator of the differentiation and 
maturation of osteocytes from osteoblasts (15,16). However, how this molecule 
regulated this process, or which signaling pathways control it were largely unknown. To 
date, one of the well-known mechanisms was that DMP1 could activate the ERK-MAPK 
pathway through the RGD integrin-binding domain in DMP1 (35,36). Recent studies 
also suggested DMP1 might function as a transcription factor transported into the 
nucleus via the functional NLS peptide in its C-terminal (37,39). In the nucleus, this 
protein regulated several genes that specifically control osteoblast and odontoblast 
differentiation. However, this nuclear theory was debatable. Our in vivo validation of the 
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theory indicated the nuclear-targeted DMP1 did not create biological functions that 
rescued the Dmp1-null phenotype. DMP1 functioned as an ECM protein that triggered 
the ERK-MAPK pathway. We also confirmed another underlying mechanism that 
controlled osteocyte differentiation and maturation: the canonical Wnt signaling 
pathway. The ectopic expression of Wnt/β-catenin in osteocytes caused the suppression 
of osteocyte maturation and affected function, leading to the pathogenesis of 
osteomalacia.  
Matrix DMP1 interacted with CD44 and integrin αvβ3 receptors via its RGD 
integrin-binding domain, which induced the cellular mitogen-activated protein kinase 
kinase (MEK1/2) and extracellular signal-regulated kinase (ERK1/2) activation. The 
activated ERK1/2 stimulated the translocation of phosphorylated JNK [also known as 
“stress-activated protein kinase” (SAPK)] to the nucleus and concomitant up-regulation 
of transcriptional activation. The ERK-MAPK pathway was involved in several cellular 
activities, including gene expression, cellular differentiation, mitosis, and cell survival 
(34-36,149). The osteocyte producing SOST and DKK1 were identified as antagonists of 
the canonical Wnt/β-catenin signaling pathway via binding to Lrp co-receptors to 
prevent interactions with Wnts (150,151). In the absence of Wnts, excess β-catenin was 
quickly sequestered by a protein complex containing Axin1/2, Apc, Ck1 and Gsk3β, and 
then phosphorylated and degraded by ubiquitin-mediated proteolysis (111,152-160). 
These down-stream signals from both the ERK-MAPK and Wnt/β-catenin signaling 
pathways resulted in down-regulation of osteoblastic genes (Osx, Col I, Alp, Bsp, Fgf23) 
but also an increase of osteocytic genes (Sost, Dkk1 and Dmp1), further promoting the 
osteoblast-osteocyte transition and the maturation process of the osteocytes. The 
decreased FGF23 production in the osteocytes kept the serum FGF23 at a specific level 
that targeted the kidney and enabled the reabsorption of Pi, thereby keeping a relatively 
high serum Pi level. By diminishing the Wnt/β-catenin signaling activity in the 
osteocytes, the serum PTH was also kept at a certain level. The elevated activity of 
ERK-MAPK signaling, together with a decreased expression of Wnt/β-catenin signaling, 
will: 1) promote the osteoblast-osteocyte transition and the maturation process of the 
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osteocyte; and 2) keep serum FGF23 and Pi at specific levels that contribute to normal 
skeletal development and bone homestasis (Fig. 5-1, a). 
On the other hand, in the absence of DMP1, ERK-MAPK signaling was down-
regulated, possibly causing the reduction of the osteocytic DKK1 and SOST. 
Consequently, Wnts bound to the co-receptors and activated Wnt/β-catenin signaling in 
the osteocyte. As a result, a decrease of osteoblastic protein expression (OSX, Col I, 
BSP, OPN, ALP, FGF23) in the osteocytes was suppressed, leading to a disturbed 
differentiation and maturation process and causing osteomalacia. In addition, the lower 
Pi level (due to excess FGF23) promoted the hypophosphatemia phenotype (Fig. 5-1, b).  
 
Pathogenesis of the Inherited Hypophosphatemic Rickets/Osteomalacia 
This study produced a more comprehensive understanding of the pathological 
and biochemical regulation of hypophosphatemic rickets/osteomalacia. The inherited 
hypophosphatemic rickets/osteomalacia phenotype includes two major characteristics: 1) 
lower serum Pi levels causing hypophosphatemia, growth plate expansion, short stature 
and developmental retardation; and 2) osteomalacia, characterized by inadequate or 
delayed mineralization of osteoid in mature cortical and spongy bone. For the last 
several decades, the disorder of the functional axis of the FGF23-renal phosphorus 
reabsorption-serum phosphorus level was established as the major pathogenesis for 
inherited hypophosphatemia (24). This study clearly demonstrated that, in addition to the 
phosphate waste caused by increased FGF23, the osteocytic up-regulation of Wnt/β-
catenin played an important pathological role in the development of osteomalacia. 
Therefore, for the clinical therapy of patients, the oral phosphate therapy should be 
further extended, and a genetic targeting drug, which would down-regulate the Wnt/β-
catenin activity in osteocytes, should be developed for a better therapeutic treatment. 
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APPENDIX A 
FIGURES 
 
 
Figure 1-1  Photographs and radiographs of patients with hypophosphatemic rickets (left 
panel) osteomalacia (right panel). (Adapted from “ASBMR educational materials”) 
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Figure 1-2  Schematic structure of the human DMP1 gene and ARHR mutations. (a) Dmp1 
gene contains by 6 exons, and because of the recessive nature of this disease, there are only 7 
variable mutations reported in the literature (see text for details). (b) DMP1 protein is reported 
mainly in the extracellular matrix since there is a secretive signal peptide in its N-terminal. 
Besides, full-length DMP1 protein very likely represents a precursor form, and will be processed 
into 37-kDa N-terminal and 57-kDa C-terminal fragments.  
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Figure 1-3  Defective osteocytes are responsible for abnormal bone formation in the Dmp1 
knockout (KO) mice (right panels). (a) Backscattered scanning electron microscopic (BSEM) 
images revealed the expanded and poorly organized growth plate (GP) in the Dmp1 KO femur, 
and severe defects in mineralization as reflected by discontinuous mineral content in the cortical 
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bone region; (b) The Goldner stain showed sharp increases in osteoid areas (red) but greatly 
reduced mature bone (green) in the KO bone; and (c) BSEM images revealed that the mineral 
was evenly distributed surrounding the osteocyte lacunae in the control bone (left, white); 
however, the mineral content was either missing, or sparsely located in regions surrounding the 
Dmp1-KO osteocytes. 
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Figure 1-4  SEM images of the acid-etched, resin-casted osteocyte-canalicular system. Note 
the differences between the control (left) and the Dmp1-null (right) in distribution, size and 
surface of osteocytes. (Adapted from Feng et al., 2006)  
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Figure 1-5  Roles of DMP1 in control of osteocyte maturation.  The gene expression levels 
are high during differentiation of osteoblasts from preosteoblasts, whereas the gene expression 
levels are gradually reduced during osteocyte maturation from osteoid osteocyte-early osteocyte 
and then mature osteocytes. DMP1 is one of the key players during this process. The loss of 
Dmp1 in mice or DMP1 mutations in humans will disrupt normal osteoblast to osteocyte 
maturation. As a result, these immature osteoblast-like osteocytes express high levels of many 
osteoblast markers (RunX2, OSX, Col I, ALP, BSP, and OCN) and early osteocyte markers such 
as E11 in bone matrices. 
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Figure 1-6  Proposed models for DMP1 control genes critical for osteogenesis.  DMP1 either 
acts as an extracellular matrix (ECM) protein that binds to integrin αvβ3/CD-44 via its RGD 
domain and activates the MAPK signaling pathway (a), or as a transcriptional factor (TF) that 
targets the nucleus (b). The end results are that the genes critical for mineralization are activated.    
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Figure 1-7 Schematic representation of ostoecytes and their connections. An embedded 
osteocyte located within its lacuna, illustrating its dendritic processes passing through the bone 
matrix (gray shading) within narrow tunnels termed canaliculi. The osteocyte’s dendritic 
processes interconnect with other osteocytes as well as surface osteoblasts. Note that some 
osteocyte processes may extend beyond the osteoblast layer to potentially interact with cells in 
the marrow and that osteocyte dendrites are also in intimate contact with the vasculature. The 
composition of the perilacunar matrix immediately adjacent to the osteocyte (mauve shading) is 
different from that of the rest of the bone matrix (gray shading), which may influence the 
magnitude of mechanical strains perceived by the osteocyte. (Adapted from Dallas et al., 2013) 
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Figure 2-1  Dmp1 is expressed in postnatal osteoblasts and responsible for regulating 
osteoblast proliferation and differentiation. (a) X-gal staining of HET long bone displayed 
blue positive cells not only in the osteocytes (Ocy) but also in the osteoblasts (Ob) in both the 
embryonic day 16.5 (insert) and the postnatal 3 weeks, especially in the metaphysis (right 
image). (b) Representative radiographs of the 10-day-old long bones indicate co-exist of the 
expanded metaphysis and the delay formed epiphysis. Dmp1-null long bone shows a delayed 
formation of epiphysis (arrowhead) and expanded metaphysis (arrows) compared to the age-
matched control bone. (c-e) Histological images showed that in the Dmp1-KO tibia metaphysis 
(right panels) there was a sharp expansion of bone masses containing little cartilage residue (c, 
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safranin O stain, 6 weeks), which indicated a lack of endochondral bone formation but active 
intramembranous bone formation. The von Kossa stain (d, 3 months) displayed poor 
mineralization, and the toluidine stain (e, 3 months) revealed a large amount of increased 
osteoblast-like cells (arrowheads) with essentially no red blood cells (RBC) compared to the 
control (left). (f-i) In situ and immunohistochemical staining showed that in the KO tibia 
metaphysis (right images), there were increases in the BrdU positive cells (f), Runx2 mRNA (g), 
Pthr mRNA (h, Pthr), and OSX protein (i).  
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Figure 2-2  Transfection of Ad-CMV-NLSDMP1 or Ad-CMV-SPDMP1 greatly changed 
expressions of bone markers in MC3T3 cells. (a) Left panel: schematic constructs of NLSDMP1 
and SPDMP1, in which the CMV promoter was used to drive the full-length Dmp1 cDNA. In 
NLSDMP1 the endogenous DMP1 signal peptide aa1-aa16 (MKTVILLVFLWGLSCAL) was 
replaced by the nuclear localization signal peptide (NLS, PPKKKRKV, upper) in contrast to the 
SPDMP1 with its endogenous signal peptide (lower). Right panel: significantly high mRNA 
expressions of Dmp1 were detected after 48-hour transfection. (b) Significant changes in mRNA 
levels of Bsp, Alp, Ocn, Opn, Dspp, and Sost in both experimental groups with an identical trend. 
The real-time PCR data, normalized with Gapdh (as an internal control), are presented as mean ± 
SEM; n=4 in each group; *P<0.05; **P<0.01, compared to the control. 
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Figure 2-3  NLSDMP1 expressed in the nuclei and SPDMP1 mainly secreted in the matrix. (a) 
Schematic structure of NLSDMP1 and SPDMP1 transgenes. In the NLSDMP1 construct, the full-
length Dmp1 cDNA is driven by the 3.6 kb Col 1α1 promoter with its endogenous signal peptide 
replaced by a NLS peptide, while in the SPDMP1 construct, the same 3.6 kb Col 1α1 promoter 
was used to drive full-length Dmp1 cDNA with its endogenous secretory signal peptide. (b) 
Non-cleavaged Western bands at the position of ~105 kDa from cell lysates of the primary 
calvarial osteoblasts with the NLSDMP1 transgenes regardless of the HET or KO. (c) 
Immunohistochemistry staining of DMP1 in 3-week-old mouse long bone. DMP1 is mainly 
expressed in the HET matrix with little signal in the nucleus, compared to no positive signal in 
the matrix in KO mice. In the NLSDMP1 transgenic bone, DMP1 is detected in both the matrix 
and the nucleus of osteocytes (arrows) and osteoblasts (arrowheads), whereas the SPDMP1 is 
highly expressed in the matrix and the osteoblasts. Data demonstrate that the transgenes is 
successfully targeted in the nucleus or matrix of the bone cells only.  
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Figure 2-4  NLSDMP1 revealed no cure of rachitic phenotypes in Dmp1-null mice, however 
SPDMP1 fully rescued the defects. (a-b) Quantified data displayed a greater than 18-fold up-
regulation of serum FGF23 levels, and a decrease of more than 20% of the Pi (phosphorus) in 
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Dmp1-null mice. The overexpression of NLSDMP1 had no effect on these parameters in either the 
HET control or KO groups; however, the SPDMP1 fully restored. (c) Statistic results 
demonstrated the above changes in the proliferation zone length and the cell proliferation 
numbers in the KO groups were significant different from the control groups. Again, the 
NLSDMP1 had no apparent effect on the above changes in either the HET or the KO background, 
but SPDMP1 made functions. (e) Representative radiophotography shows short femurs with poor 
mineral remodeling in all three Dmp1-KO groups (3 wk, 6 wk and 1 year). The targeted 
expression of NLSDMP1 had no rescue effects on the length, accumulated bone masses 
(asterisks), expanded and malformed growth plates (arrows), and distorted tuberosities 
(arrowheads), all of which were fully rescued by SPDMP1. (f) Safranin O stain images of 3-
week-old tibias, in which there were two expanded regions in the KO growth plate: the 
proliferation zone (PZ, white lines) and hypertrophic zone. The NLSDMP1 transgene had no 
effect in both regions but SPDMP1 recovered this abnormality. (g) BrdU stain images indicate 
increased number of BrdU positive cells in the KO and KO+NLSDMP1 groups. (h-k) In situ and 
immunohistochemical staining show the molecular changes of the chondrogenic genes in the 
Dmp1-KO background (right images), including Runx2 mRNA (i), sonic hedgehog mRNA (Shh, 
j), SOX9 (k), and OSX (l). Data indicate an increase in cell proliferation and differentiation in 
the Dmp1-null mice, most likely due to hypophosphatemia. (Data are presented as mean ± SEM; 
n=5; *P<0.05; compared to the control). 
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Figure 2-5  Targeting DMP1 in the Dmp1-KO nuclei did not rescue deficiencies of 
mineralization in Dmp1-null mice, however re-expressing DMP1 in the matrix greatly 
recovered these defects. (a-c) Compared to SPDMP1, NLSDMP1 had no effect on bone shape and 
secondary ossification (a, alizarin red/alcian blue stains, arrows), bone porosity and 
mineralization reflected by uCT images (b, arrowheads) and Goldner stain (c, red indicating a 
lack of minerals). (d) SEM images of the acid-etched, resin-casted osteocyte-canalicular system. 
Note the KO+NLSDMP1 osteocyte shown the same appearance with the KO osteocyte, indicating 
nuclear activities of DMP1 had no apparent effect on the osteocyte-lacunocanalicular system.  
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Figure 2-6  IHC analysis shown the targeted expression of NLSDMP1 transgene revealed no 
rescue of the maturational defects in ostecytes. (a) Immunohistochemistry assay of decorin of 
3-week mouse long bones, brown indicates positive staining. (b) An increase in the expression of 
OXS in KO osteocytes and the KO+NLSDMP1 osteocytes (arrows). (c) Arrows indicate that 
widely expressed E11 throughout the cortical bone of KO and the KO+NLSDMP1 mouse 
(arrows). (d) The staining for SOST shows the osteocytes, in the KO and the KO+NLSDMP1 
groups, did not express or weakly expressed the SOST (arrows).  
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Figure 2-7  The targeted expression of NLSDMP1 transgene (line #2097) in either the Dmp1 
HET or the KO background had no effect. (a-b) Representative radiograph images showed 
that the NLSDMP1 transgene in the HET osteoblast and osteocyte had no apparent effect, and this 
transgene did not rescue Dmp1-KO phenotype. (c) H&E staining images, revealed no rescues on 
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the Dmp1-KO skeleton abnormalities, including expanded hypertrophic chondrocyte zone and 
malformed metaphysis. 
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Figure 2-8  The in vivo working model. (a) DMP1, secreted from the cell, binds to integrin via 
its RGD domain, followed by activation of the MAP kinase signaling pathway (34,35). The 
targeted expression of DMP1 in the nucleus has no direct role in osteogenesis in vivo. (b) DMP1, 
expressed in the osteoblast, facilitates cell proliferation and transformation directly from 
osteoblasts into osteocytes. Deletion of Dmp1 leads to an increase in cell proliferation and a 
reduction in osteoblast cell differentiation. Because of the great increase of FGF23 in Dmp1-KO 
osteocytes, the reduced Pi brings on an increase in cell proliferation and differentiation in 
chondrocytes (a new indirect role of hypophosphatemia in the growth plate), in addition to the 
abnormality in the apoptosis process (18). 
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Figure 3-1  Tooth phenotypes in an M1V Mut ARHR patient. (a) Comparison of the amino 
acid sequence of the NH2-terminal region of the DMP1 across species, including the M1V 
mutant human DMP1. (b) Radiographs from an adult (20+ years old) ARHR patient (upper 
panel) and the age-matched control (lower panel). Arrows show the enlarged pulp cavities and 
root canals and reduced dentin thickness in the patient, compared to the control.  
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Figure 3-2  Nucleus-targeted Dmp1 expressed in the pre-odontoblasts and odontoblassts, 
showing no morphological improvement of Dmp1-null tooth. (a) Dmp1 expression was 
analyzed in the first molars of 3-week-old mice by immunohistochemical staining using anti-
Dmp1-C-terminal antibody (signal in brown color). (b-c) Higher magnification of the boxed 
areas in (a) demonstrated the presence of Dmp1 in the odonto-lineage and dentinal matrix. (b) 
Localization of NLSDMP1 in the nuclei, cytoplasm and dendrites of odontoblasts (arrows). (c) 
Localization of NLSDMP1 in the nuclei of pre-odontoblasts (arrows). (d) Representative 
radiographs of 6-week-old mouse mandible. Note the enlarged pulp cavities and root canals 
(arrows), and the thinner dentin (arrowheads) in both KO and KO+NLSDMP1 mice.  
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Figure 3-3  Nucleus-targeted Dmp1 had no rescue of the dental abnormalities of Dmp1-null 
mice.  (a) Toluidine Blue staining of the first molars of 3-week-old mice. Note the thinner crown 
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dentin (arrows) in both KO and KO+NLSDMP1 tooth. (b) Higher magnification of the boxed area 
in (a). Note the widened predentin (arrows) with thinner dentin in KO and KO+NLSDMP1 mice. 
(c) The toluidine blue staining of 6-week-old mouse dentin. Note the widened predentin (arrows) 
with reduced dentin thickness, as well as the presence of interglobular dentins (arrowheads) in 
KO and KO+NLSDMP1 mice. (d) Sirius Red staining sections imaged under polariscope. The 
orange color indicates larger collagen fibers, whereas the green color means thinner collagen 
fibers such as reticular fibers. (e) Anti-DSP-antibody staining of 3-week-old mice. DSP was 
down regulated in the odontoblasts (arrows) and dentinal matrix (asterisks) of the KO and 
KO+NLSDMP1 mice. (f) Images of dentinal tubular system from resin-casted acid-etched electron 
microscopy. Note the dendritic branches are fewer and disorganized in the KO and 
KO+NLSDMP1 mice. Notes: PL, periodontal ligament; Dn, dentin; P, pulp; En, enamel; pDn, 
predentin. 
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Figure 3-4  Dmp1-null mice developed typical periodontitis. (a) Radiographs of 1-year-old 
mouse tooth. Note the periodontal-endodontic combined lesions in the second molar (arrows), 
and the exfoliation of the second molar (arrowheads). (b-c) Occlusal and buccal photographs of 
1-year-old mouse tooth. Note the periodontitis with notable loss of periodontal attachment 
(arrows), and the exfoliation of the second molar with alveolar bone absorption (arrowheads). 
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Figure 3-5  Nucleus-targeted Dmp1 had no improvement of periodontal structures. (a) 
Sirius Red staining imaged under light microscopy (3-week-old mouse molars). Dark red 
indicated more collagen contents, light red meant less collagen contents. (b) Same sections of (a) 
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but imaged under polarized light (3-week-old mouse molars). (c) Anti-biglycan antibody staining 
of 3-week-old mouse molars. The biglycan was increased in the widened predentin (arrowheads) 
and the matrix of alveolar bone (asterisks), but was decreased in the PDL (arrows) in KO and 
KO+NLSDMP1 groups. (d-e) Back-scatter electron microscopy of alveolar bone. KO and 
KO+NLSDMP1 groups show trabeculae disorganization and hypomineralization. Notes: AB, 
alveolar bone. 
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Figure 3-6  Nucleus-targeted Dmp1 showed no effect on tooth eruptional delay. (a-b) 
Representative radiographs and micro-CT images of 10-day-old mice mandibles. The bony 
crypts (arrows) indicate where the third molar will develop in the HET and HET+NLSDMP1 
mice; whereas they were barely visible in KO and KO+NLSDMP1 mice. In addition, the occlusal 
surface (arrowheads) of the first molars of was partially embedded in the bony crysts in both KO 
and KO+NLSDMP1 mice. (c) Representative radiographs of 3-week-old mouse tooth, note the 
partially eruption of the third molars (arrows). (d) TRAP staining of the metaphysis (at 3 weeks). 
In the primary spongiosa region, the number of TRAP positive cells (red) was significantly 
reduced in the Dmp1-KO and the KO+NLSDMP1 mice. Notes: 1st, first molar; 2nd, second molar, 
3rd, third molar. 
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Figure 3-7  (a-b) Shown are the length (mm) of the roots (a) and the thickness (mm) of the 
dentin layer (b) from 3-week-old mice. Data are mean ± SEM; n=6 in each group; *P<0.05; 
**P<0.01, compared to the control (HET). (c) Statistic analysis of the number of osteoclasts in 3-
week-old mice. Data are mean ± SEM; n=4 in each group; *P<0.05, compared to the control. (d) 
Radiographs of the 3-week-old mandibles of another independent line (line #97). Typical dental 
and condylar defects can be found in KO and KO+NLSDMP1 mice. 
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Figure 4-1  A sharp reduction of SOST expression in the 3-wk-old cortical bone of Dmp1-
null mice. The representative immunohistochemistry image displayed a high level of sclerostin 
in the mature osteocytes and dendrites (left) compared to the age-matched Dmp1-KO tibia, 
where SOST was largely undetectable (right images).  
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Figure 4-2  Wnt/β-catenin signaling was up-regulated in the osteocyte of Dmp1-null mice. 
(a) The mRNA expression level of β-catenin showed a more than 15-fold up-regulation in 
Dmp1-null mice compared to the controls. Data are presented as mean ± SEM; n=6 in each 
group; *P<0.05; **P<0.01. (b) Immunohistochemistry staining of β-catenin revealed an 
increased expression of β-catenin in the osteocytes. The arrow in the magnified box indicated a 
nuclear localization of β-catenin. (c) X-gal positive osteocytes were found in the Dmp1 
conditional knockout (3.6 kb Col1 Cre; Dmp1fx/fx; Top-gal+) mouse long bones (arrows), 
compared to few positive osteocytes in the control group (Dmp1fx/fx; Top-gal+). Note the β-
galactosidase gene was driven by a TCF-β-catenin responsive promoter in the Top-gal mouse, so 
canonical Wnt activity was detected by X-gal staining. (d) In situ hybridization staining 
demonstrated the Tcf expression that was up-regulated in the osteocytes of Dmp1-null mice 
(arrows).  
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Figure 4-3 Constitutive stabilization of β-catenin in osteocytes led to abnormal bone 
structures at age of 3 weeks. Compared to the control group, CA-β mice display typical 
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hypophos-phatemic rickets/osteo-ma-lacia phenotype, including short stature and long bone size 
(a), cortical bone porosity (b), and osteocyte proliferation (c). Data are presented as mean ± 
SEM; n=4 in each group; *P<0.05; **P<0.01.  
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Figure 4-4 Constitutive stabilization of β-catenin in osteocytes recaptured osteomalacia 
phenotype and displayed deformed osteocytes. (a-c) Elevated β-catenin levels in offspring of 
CA-β (Dmp1-Cre; β-catex3loxP/+) mice resulted in osteomalacia indistinguishable from that in 
Dmp1-KO mice, as evidenced by: polarized light images, in which green means thinner collagen 
fibers such as reticular fibers, whereas red or orange indicates larger collagen fibers such as 
collagen type I,  showing increased disorganized collagen (a); Biglycan staining that appeared 
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more positively stained area (b); Goldner-stained sections of bone, which exhibited abundant 
red-staining osteoid (c). (d-g) Increased β-catenin levels in osteocytes caused maturation defects, 
as supported by immunostains of osteoblast and early osteocyte markers, such as OSX (d), OPN 
(e), and E11 (g) showed apparently elevated expressions; BrdU staining that documented 
increased proliferation of the immature osteocytes in the osteoid (g).  
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Figure 4-5  Normalizing the Wnt/β-catenin activity greatly improves the bone morphology. 
(a-b) Representative radiographs of 3-wk (a) and 8-wk (b) groups. Note the long bone shape was 
better formed in the DKK1; KO mice, compared to the KO groups. Also, in the KO mice, the 
bone accumulation appeared in the metaphysis (arrowhead) and the epiphyseal structures were 
disorganized and malformed (arrows), but were notably improved by Dkk1-Tg. (c) µ-CT images 
of different tibia cross sections indicated malformed epiphysis structure, obvious bone 
accumulation in the metaphysis (arrow), and porous cortical bone (arrowhead) in the KO mice, 
which was partially rescued by Dkk1-Tg. (d-f) Statistical analysis of epiphysis area (d), tibia 
length (e), and cortical porosity (f) indicated significances between KO and DKK1; KO groups. 
Data are presented as mean ± SEM; n=5 in each group; *P<0.05; **P<0.01.  
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Figure 4-6  Immunohistochemistry staining of DMP1, DKK1, and β-catenin. (a) In the WT 
groups, endogenous DMP1 was detected in the bone matrix and osteocytes, compared to no 
signal in the KO groups (asterisk). (b) Endogenous DKK weakly expressed in the osteocytes 
compared to little signal was detected in the Dmp1-null osteocytes (arrowheads). The transgenic 
DKK1 highly expressed in both osteocytes (arrowheads) and osteoblasts (arrows), consistent 
with the activity of its 2.3 Col1α1 promoter. (c) β-catenin increased in both osteoblasts (arrow) 
and osteocytes (arrowhead) of Dmp1-null mice, which was down-regulated in DKK1; KO group.  
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Figure 4-7  The abnormal bone homeostasis in Dmp1-null metaphysis is improved by Dkk1-
Tg. (a-c) Immunohistochemistry staining of the osteoblastic markers, including OSX (a), BSP 
(b) and OPN (c), abundantly increased in the KO metaphysis, together with significantly 
increased cell proliferation activity (d, f), suggesting there is an enhanced bone formation in the 
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Dmp1-null metaphysis, which is partially rescued in the DKK1; KO mice. (e, g) Analysis of 
TRAP staining showed a significant restoration of osteoclast numbers in the DKK1; KO groups. 
Data are presented as mean ± SEM; n=4 in each group; *P<0.05; **P<0.01.  
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Figure 4-8  Osteomalacia phenotype in Dmp1-null mice was greatly restored by Dkk1-Tg. 
(a) The double fluorochrome labels displayed identical bone-formation rates in WT and DKK1; 
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WT were similar to the DKK1; KO mice but in contrast to the diffuse label (arrows) in the KO 
mice at the age of 4 weeks. (b-d) Cortical bone mineralization showed an apparent restoration in 
the DKK1; KO mice, evidenced by: Goldner staining (b, arrows); Sirius red-stained sections (c, 
asterisks) imaged under light microscopy (upper panels) and polarizing microscope (lower 
panels); anti-biglycan staining (d, asterisks).  
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Figure 4-9  Osteocyte maturation defect in Dmp1-null mice is greatly improved by Dkk1-
Tg. (a-c) Immunohistochemistry staining of the bone cell markers. (a) Osteoblastic marker 
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(OSX) is expressed in Dmp1-null osteocytes (arrow) but not in DKK1; KO. (b) Early osteocytic 
marker (E11), which is mainly expressed in the newly formed osteocytes (arrowheads) and 
widely detected in the KO mice (arrow). (c) Mature osteocytic marker SOST broadly expressed 
in the mature osteocyte but decreased in the Dmp1-null osteocyte (arrows). (d) Backscattered 
SEM displayed a notable restoration of osteocyte morphology together with a great improvement 
in the precellular mineralization in KO; DKK1 sample, compared to the malformation and 
hypomineralization of the Dmp1-null mice (arrows). (e) Representative BrdU-stained long bone 
sections showed that BrdU+ cells increased in number and distribution in the Dmp1-null cortical 
bone (arrows). In contrast, there were fewer BrdU+ cells detected in the DKK1; KO samples.  
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Figure 4-10  Hyp-mice displayed increased β-catenin level and Dkk1-transgene produced a 
morphological rescue in Hyp-mice. (a) Serum FGF23 level in the Hyp-mice significantly 
increased (>1000-fold). (b-c) mRNA expression levels of fgf23 and β-catenin. Significant 
increases can be found in both fgf23 mRNA (b, >2-fold) and β-catenin mRNA (b, >9-fold). Data 
are presented as mean ± SEM; n=5 in each group; *P<0.05; **P<0.01. (d) Western blot analysis 
of 3 different pairs confirmed that the protein levels of β-catenin are higher in Hyp-mice, 
compared to the WT control. (e) Representative radiographs of mouse long bones. Both 
epiphyseal structure (arrowheads) and abnormal bone accumulation in metaphysis (arrows) were 
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partially rescued in DKK1; Hyp mice. (f) HE staining further indicates the bone trabeculae in 
tibia metaphysis is better organized in DKK1; Hyp mice, compared to Hyp-mice. 
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Figure 4-11  Injection of anti-β-catenin compound drug improved the rickets/osteomalacia 
deficiency in Dmp1-null mice. (a) Representative radiographs of mouse long bones. Both 
metaphysis (arrowheads) and growth plate (arrows) were partially rescued in the Dmp1-null 
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mice with IWR compound treatment. (b-c) Epiphyseal structure (asterisks), growth plate 
expansion (arrowheads), metaphyseal bone accumulations (arrows), bone porosity (c, arrows) 
are improved in the IWR-1 injected Dmp1-null mice.  
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Figure 4-12  The pathogenesis of the inherited hypophosphatemic rickets/osteomalacia in 
Dmp1-null or Hyp-mice. The loss-function of DMP1 in Dmp1-null mice or Hyp-mice caused 
decreased SOST secretion, which leads to the constitutive stabilization of β-catenin in 
osteocytes. This ectopic Wnt/β-catenin signaling activity regulated bone-related gene expression, 
such as Osx, Col I, Alp, Bsp, E11, etc., affecting osteoblast-osteocyte transition and/or osteocyte 
maturation and bone mineralization. In contrast, the absence of functional DMP1 also led to the 
abnormal expression of FGF23, which was secreted from osteocytes and targeted the kidneys, 
leading to Pi waste and higher serum Pi, a major characteristic of hypophosphatemia.  
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Figure 5-1  Signaling pathways underlying the osteocyte maturation and function 
process that was regulated by DMP1.  
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APPENDIX B 
TABLES  
Table 1-1  Characteristics of ARHR patients and mice models 
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Table 2-1  Three independent lines and their DMP1 expressions  
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Table 2-2  RNA expression levels after transfection  
 
 
Values are expressed as mean ± SEM from at least 4 samples per group. Comparisons were performed 
using one-way ANOVA and post-hoc Fisher test. SP: Significant differences, P<0.05 vs:(*) control;  
P<0.01 vs:(**) control.  
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Table 2-3  Bone Histomorphometry Findings in the femurs of 3-week-old mice   
Values are expressed as mean ± SEM from at least 5 mice per group. Comparisons were performed using 
one-way ANOVA and post-hoc Fisher test. P<0.05 vs:(*) Dmp1+/-;  P<0.01 vs:(**) Dmp1+/- of femur 
length, cross section area, TV, BV, BV/TV, cortical porosity. P<0.05 vs:(*) DMP1+/-;  P<0.01 vs:(**) 
DMP1+/- of ectopic BV.  
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Table 4-1  Hypophosphatemia phenotype in Dmp1-null mice was partially rescued 
by Dkk1-Tg.  
 
Phosphorus	  (mg/dL) FGF23	  (pg/mL) Calcium	  (mg/dL) PTH	  (pg/mL)
Control 8.664 ± 0.9868 155.1	  ±	  18.55	   9.820	  ±	  0.5148	   42.07	  ±	  5.664	  
CA-­‐β 6.964	  ±	  0.4852	   196.1	  ±	  47.56	   9.866	  ±	  0.5095 1485	  ±	  419.3	  **
Value	  are	  expressed	  as	  mean	  ±	  SEM	  from	  at	  7	  mouse	  per	  group.	  P<0.05	  vs:(*)	  Control;	  	  P<0.01	  vs:(**)	  Control.
WT 14.43	  ±	  0.9822	   160.8	  ±	  9.387	   11.03	  ±	  0.4182	   61.30	  ±	  17.72	  
WT;	  DKK1-­‐Tg 15.31	  ±	  0.7880	   215.8	  ±	  13.42	   10.72	  ±	  0.5485	   86.20	  ±	  21.14	  
KO 7.766	  ±	  0.4509 2781	  ±	  426.7	   9.580	  ±	  0.4211	   313.2	  ±	  41.46	  
KO;	  DKK1-­‐Tg 9.455	  ±	  0.6110	   1840	  ±	  233.4 10.84	  ±	  0.5536	   170.7	  ±	  38.52	  
Value	  are	  expressed	  as	  mean	  ±	  SEM	  from	  at	  14	  mouse	  per	  group.	  P<0.05	  vs:(*)	  Control;	  	  P<0.01	  vs:(**)	  Dmp1 -­‐KO.
WT 11.24 ± 0.6448 196.1	  ±	  11.69 14.34	  ±	  1.540 34.75	  ±	  8.138
WT;	  DKK1-­‐Tg 13.02	  ±	  0.4484	   134.1	  ±	  19.55 15.92	  ±	  0.5091 24.88	  ±	  6.975	  
Hyp 6.197	  ±	  0.2412	   1786	  ±	  264.5 12.01	  ±	  0.9157 68.00	  ±	  12.79	  
Hyp;	  DKK1-­‐Tg 8.584	  ±	  0.4236 2362	  ±	  767.6 11.68	  ±	  0.7565 47.00	  ±	  16.22	  
Value	  are	  expressed	  as	  mean	  ±	  SEM	  from	  at	  5	  mouse	  per	  group.	  P<0.05	  vs:(*)	  Control;	  	  P<0.01	  vs:(**)	  Hyp
